

## AHA SCIENTIFIC STATEMENT

# Atrial Fibrillation Occurring During Acute Hospitalization: A Scientific Statement From the American Heart Association

Janice Y. Chyou, MD, FAHA, Chair; Ebrahim Barkoudah, MD, MPH; Jonathan W. Dukes, MD; Larry B. Goldstein, MD, FAHA; Jose A. Joglar, MD, FAHA; Anson M. Lee, MD; Steven A. Lubitz, MD, MPH, FAHA; Keith A. Marill, MD, MS; Kevin B. Sneed, PharmD; Megan M. Streur, PhD, ARNP; Graham C. Wong, MD, MPH, FAHA; Rakesh Gopinathannair, MD, MA, FAHA, Vice Chair; on behalf of the American Heart Association Acute Cardiac Care and General Cardiology Committee, Electrocardiography and Arrhythmias Committee, and Clinical Pharmacology Committee of the Council on Clinical Cardiology; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation; Council on Cardiovascular and Stroke Nursing; and Stroke Council

**ABSTRACT:** Acute atrial fibrillation is defined as atrial fibrillation detected in the setting of acute care or acute illness; atrial fibrillation may be detected or managed for the first time during acute hospitalization for another condition. Atrial fibrillation after cardiothoracic surgery is a distinct type of acute atrial fibrillation. Acute atrial fibrillation is associated with high risk of long-term atrial fibrillation recurrence, warranting clinical attention during acute hospitalization and over long-term follow-up. A framework of substrates and triggers can be useful for evaluating and managing acute atrial fibrillation. Acute management requires a multipronged approach with interdisciplinary care collaboration, tailoring treatments to the patient's underlying substrate and acute condition. Key components of acute management include identification and treatment of triggers, selection and implementation of rate/rhythm control, and management of anticoagulation. Acute rate or rhythm control strategy should be individualized with consideration of the patient's capacity to tolerate rapid rates or atrioventricular dyssynchrony, and the patient's ability to tolerate the risk of the therapeutic strategy. Given the high risks of atrial fibrillation recurrence in patients with acute atrial fibrillation, clinical follow-up and heart rhythm monitoring are warranted. Long-term management is guided by patient substrate, with implications for intensity of heart rhythm monitoring, anticoagulation, and considerations for rhythm management strategies. Overall management of acute atrial fibrillation addresses substrates and triggers. The 3As of acute management are acute triggers, atrial fibrillation rate/rhythm management, and anticoagulation. The 2As and 2Ms of long-term management include monitoring of heart rhythm and modification of lifestyle and risk factors, in addition to considerations for atrial fibrillation rate/rhythm management and anticoagulation. Several gaps in knowledge related to acute atrial fibrillation exist and warrant future research.

**Key Words:** AHA Scientific Statements ■ atrial fibrillation ■ critical illness ■ hospitalization ■ postoperative period

**A**trial fibrillation (AF) can manifest in a broad range of acute medical and surgical conditions. Although previously postulated as transient and isolated events, accumulating evidence suggests that AF detected in the setting of acute care or acute illness is associated with a high risk of long-term AF recurrence,<sup>1–15</sup> warranting attention during acute hospitalization and long-term follow-up as well as the need for specific guidance. Serving as a dedicated expansion

on this subject beyond management of AF addressed in existing guidelines,<sup>16–18</sup> this scientific statement will specifically address existing knowledge, practical management considerations, and opportunities for future research on AF that acutely manifests in the setting of acute care or acute illness, including during hospitalization for another condition.

The writing group has reviewed data from randomized clinical trials (RCTs), registries, and observational studies.

Supplemental material is available at <https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000001133>.

© 2023 American Heart Association, Inc.

Circulation is available at [www.ahajournals.org/journal/circ](http://www.ahajournals.org/journal/circ)

Given the broad reach of this topic, we expect a multidisciplinary audience for this scientific statement, including cardiologists, cardiac electrophysiologists, nursing and allied health professionals, cardiac surgeons, anesthesiologists, surgical specialists, intensivists, hospitalists, internists, emergency department (ED) physicians, neurologists, and pharmacists.

## Definitions

In this scientific statement, we introduce the term acute AF. Acute AF is defined as AF detected in an acute care setting or during an acute illness. Acute AF has sometimes been referred to as secondary AF in prior literature. The writing group chose to move away from the term secondary AF because it is often unclear whether AF detected in acute care settings is truly secondary to or attributable to the acute issue and would not have otherwise arisen. In other words, AF might have been present in the individual before the acute illness but not previously diagnosed or detected.

Therefore, this characterization of AF as acute AF pertains to the contextual presentation of AF, that is, AF detected or managed for the first time during acute illness such as during acute hospitalization for another condition. The acute AF may be paroxysmal or persistent. The acute AF may be symptomatically felt by the patient or asymptotically detected on rhythm monitoring or ECG. The further characterization of acute AF (as paroxysmal/persistent, symptomatic/asymptomatic) is consistent with existing clinical documents.<sup>18,19</sup> General definitions and classifications of AF were provided in the 2014 American Heart Association/American College of Cardiology/Heart Rhythm Society guideline on management of AF<sup>16</sup> and in the 2017 Heart Rhythm Society/European Heart Rhythm Association/European Cardiac Arrhythmia Society/Asia Pacific Heart Rhythm Society/Latin American Society of Cardiac Stimulation and Electrophysiology expert consensus statement on catheter and surgical ablation of AF.<sup>19</sup>

## Scope of the Issue and Public Health Significance

Acute AF is increasing in incidence<sup>20</sup> and manifests across a range of medical and surgical settings. In medical patients, the incidence ranges from 1% to 46% across different patient cohorts.<sup>1,21–24</sup> In patients with sepsis, the incidence of acute AF varies with the severity of sepsis, with an incidence of 8% to 10% in sepsis, 6% to 22% in severe sepsis, and 23% to 44% in septic shock.<sup>1,21,23,24</sup> Acute AF is associated with longer length of hospitalization,<sup>23–25</sup> greater morbidity<sup>15,21,22,26</sup> and mortality,<sup>21,23,26–28</sup> and high rates of recurrent AF.<sup>1,15</sup>

In the surgical setting, acute AF occurs in the setting of both noncardiac and cardiac surgery. In the context of noncardiac surgery, depending on the type of noncardiac surgery, 3% to 16% of patients develop acute AF,<sup>5</sup> the occurrence of which has been associated with longer hospitalization,<sup>29</sup> greater morbidity<sup>30–33</sup> and mortality,<sup>31–33</sup> higher costs,<sup>29</sup> and subsequent AF recurrence.<sup>5</sup>

AF occurring acutely after cardiac surgery is a specific form of acute AF. Postoperative AF in the setting of cardiac surgery is common, affecting ≈32% of patients after coronary artery bypass grafting, 49% of patients after concomitant coronary artery bypass grafting and aortic valve replacement, and 64% of patients after coronary artery bypass grafting and mitral valve replacement,<sup>34</sup> with high rates of recurrence over subsequent years.<sup>9,11,12</sup> Development of postoperative AF after cardiac surgery is associated with longer hospitalization,<sup>35,36</sup> greater short-term<sup>35,37</sup> and long-term morbidity,<sup>38–40</sup> greater mortality,<sup>35,37–39,41</sup> recurrent hospitalizations,<sup>42</sup> and consequently increased cost of care.<sup>43</sup> Thus, regardless of the hospitalization setting, acute AF is not benign.


## SUBSTRATES AND TRIGGERS OF ACUTE AF

A conceptual model incorporating considerations of both substrates and triggers can serve as a useful framework for approaching acute AF (Figure 1).

Substrates for acute AF pertain to atrial scars or electrical or structural remodeling.<sup>44</sup> Atrial scars may result from chronic underlying processes<sup>45</sup> such as volume or pressure overload from valvular heart disease, cardiomyopathy, long-standing hypertension, chronic kidney disease, or myopathic states involving atrial myopathy. Substrates for acute AF may also arise from prior cardiac surgeries<sup>44</sup> (as related to scars from atriotomy, cardiopulmonary bypass, prior valvular surgery, maze procedure), thoracic surgeries, or existing pulmonary disease.<sup>45</sup> Additional substrates include pericardial fat pad<sup>46</sup> and pulmonary vein automaticity.<sup>47</sup>

Triggers for acute AF include inflammation, local mechanical stress, oxidative stress, electrolyte imbalance, and shifts in autonomic tone.<sup>44,48</sup> Potential sources of triggers include infection, pericardial effusion and inflammation, long procedural time, hemodynamic shifts, volume loss or overload, intraprocedural and postprocedural pulmonary complications, and medications, including inotropic agents.<sup>45,49,50</sup>

Acute AF can therefore be conceptualized as the provocation of the susceptible substrates by the acute triggers, leading to the manifestation of AF during acute hospitalization. Building on this concept, acute AF may represent previously unrecognized AF or unmasking of an underlying predisposition to AF in the setting of an acute trigger (Figure 2).




**Figure 1. A conceptual model of substrates and triggers of acute AF.**

AF indicates atrial fibrillation; and PV, pulmonary vein.

## DETECTION OF ACUTE AF

Physical examination may raise suspicion for AF with the identification of an irregularly irregular pulse or auscultated heart rhythm, variable intensity of  $S_1$ , or variable pulse



**Figure 2. Potential mechanistic pathways of acute AF.**

AF indicates atrial fibrillation.

amplitude. Electrocardiographic modalities for the detection of AF during acute hospitalization include 12-lead ECG on presentation for acute illness in the ED or during hospitalization or continuous electrocardiographic monitoring with inpatient telemetry. Continuity of electrocardiographic monitoring during the hospital stay influences the detection of acute AF, with continuous monitoring with telemetry being more likely to detect acute AF compared with episodic ECG.<sup>5</sup>

## Detection and Consideration for Intensity of Electrocardiographic Monitoring

Patient-based risk scores (such as the CHA<sub>2</sub>DS<sub>2</sub>-VASc score initially developed for thromboembolism,<sup>51</sup> the ATRIA score initially developed for thromboembolism,<sup>52</sup> the HATCH [hypertension, age, transient ischemic attack or stroke, chronic obstructive pulmonary disease, and heart failure] score initially developed for AF progression,<sup>53</sup> and the POAF score for postoperative AF<sup>54</sup>) have been evaluated as tools to predict acute AF in hospitalized patients.<sup>54–61</sup> Consistent with the

consideration of substrates, the risk scores can be considered a composite marker of vulnerable substrate.

Of these, the CHA<sub>2</sub>DS<sub>2</sub>-VASc score has been studied most extensively. In medical settings, the CHA<sub>2</sub>DS<sub>2</sub>-VASc score has correlated with acute AF in patients hospitalized for pneumonia,<sup>57</sup> myocardial infarction,<sup>62</sup> and stroke.<sup>55</sup> In the setting of cardiac surgery,<sup>54,56,58,59,61,63</sup> the CHA<sub>2</sub>DS<sub>2</sub>-VASc score has outperformed the HATCH or the POAF score.<sup>58</sup>

Additional factors such as type of surgery<sup>5,34</sup> and elevated BNP (brain natriuretic peptide)<sup>64,65</sup> have been associated with acute AF risks. Risk factors for acute AF in the setting of cardiac surgery have also been summarized as an expert consensus table as part of a Society of Cardiovascular Anesthesiologist/European Association of Cardiothoracic Anaesthetists practice advisory.<sup>66</sup>

Patients at higher risk for acute AF may benefit from increased intensity of electrocardiographic monitoring during hospitalization. Refining predictive and risk stratification models for acute AF is an area of active research.<sup>67</sup> Developing a framework to triage the intensity of electrocardiographic monitoring during acute hospitalization is an important area for future research.

## ACUTE MANAGEMENT

### Overview of Acute Management

Building on the conceptual framework of substrates and triggers, management of acute AF should be tailored to the patient, underlying structural substrates, and contextual triggers. Principal goals of management of AF occurring during acute hospitalization are optimization of hemodynamics, alleviation of patient symptoms, and reduction of short- and long-term risks of thromboembolism.

Acute management of AF occurring during hospitalization requires a multipronged approach. Key dimensions of acute management include identification and treatment of triggers, selection and implementation of rate/rhythm control, and management of anticoagulation.

### Acute Triggers: Identification and Treatment

A priority in the management of acute AF is the identification and treatment of potential triggers because rate and rhythm control may be less likely to succeed until the acute illness improves. Potential acute triggers and sources of acute triggers are illustrated in Figure 1. Identification and management of triggers related to a patient's acute AF would benefit from multidisciplinary partnership with the care teams managing the patient's acute hospitalized conditions.

### AF Management: Acute Rate and Rhythm Management

Because acute AF may spontaneously convert to sinus rhythm,<sup>68–72</sup> an initial rate control and delayed cardio-

version “wait-and-see” approach may be reasonable for hemodynamically stable asymptomatic patients with acute AF while acute triggers are being aggressively treated. However, physiological ramifications of AF can include decreased systemic blood pressure and cardiac output, increased pulmonary vascular pressures, and atrioventricular valve regurgitation.<sup>73</sup> Effects vary among patients and may relate to rapid ventricular rates associated with AF or atrioventricular dyssynchrony.<sup>74</sup> Given the variability in acute conditions and patient comorbidities, acute AF may have variable impact on hemodynamics and patient tolerance.<sup>75,76</sup> In hemodynamically unstable patients, immediate electrical cardioversion is the treatment of choice.


In hemodynamically stable patients, the acute rate or rhythm control strategy should be individualized with consideration of the patient's capacity to tolerate the potential rapid rates or atrioventricular dyssynchrony and the patient's ability to tolerate the risk of rate or rhythm control strategy (Figure 3). Use of a rhythm or rate control strategy depends on the patient and structural substrate, the hemodynamic consequences of AF, and the adequacy of the rate control strategy. Given the risk of acute thromboembolism with acute rhythm control of AF, any decision to proceed with a rhythm control strategy will also need to consider the risk of stroke and the need for adjunctive short- and long-term anticoagulation.

### Acute Rate Control

Rate control medications reduce the ventricular rate in AF by increasing the refractoriness of the atrioventricular node.<sup>77</sup> Rate control medications for acute AF management are summarized in [Supplemental Table 1](#). The choice of rate control agent may depend on patient characteristics and comorbidities, with specific contraindications and clinical considerations given in [Supplemental Table 1](#).

Target heart rate for optimal rate control in the setting of acute AF has not been established. Existing data suggest an initial heart rate <110 bpm as a reasonable target for hemodynamically stable outpatients (AFFIRM [Atrial Fibrillation Follow-up Investigation of Rhythm Management])<sup>78</sup> or patients with permanent AF (RACE II [Rate Control Efficacy in Permanent Atrial Fibrillation]).<sup>79</sup> Recent guidelines recommend <110 bpm as a general target for AF rate control, but a stricter target of a resting heart rate <80 bpm for patients with deterioration of left ventricular function, symptoms, concomitant cardiac resynchronization therapy, or diagnosis of tachycardia-mediated cardiomyopathy.<sup>18</sup> In the specific context of AF after cardiac surgery, rate control targeting heart rate <100 bpm is reasonable for asymptomatic patients.<sup>42,80</sup>

Further studies to determine whether a rate control target of <110 bpm may be reasonable for acute AF, with the exception of AF occurring in the setting of cardiac surgery,



**Figure 3. Approach to acute management of triggers and rate vs rhythm control strategy in acute AF.**

Assessment of the impact of AF on the patient provides a rational approach to pursue rate control or rhythm control or both. Management of acute triggers is important and facilitates the success of rate and rhythm control strategies. AF indicates atrial fibrillation.

ventricular dysfunction, or concomitant cardiac resynchronization therapy, would be helpful. A heart rate <110 bpm may be reasonable to permit some leniency while balancing diastolic filling. However, the specific optimal heart rate for a patient's acute AF may correlate with what may be hemodynamically optimal in the specific setting and may be individualized with dynamic observation of pulse pressure and mean arterial pressure as surrogates for optimal output and perfusion. In the setting of concomitant acute medical or surgical conditions, achievement of optimal heart rate will also include addressing associated acute triggers and ensuring that tachycardia is not a compensatory response to hemodynamic distress.

### Acute Rhythm Control

In hemodynamically unstable patients, immediate electrical cardioversion with direct current cardioversion (DCCV) is the treatment of choice.<sup>16,80–82</sup> In hemodynamically stable patients intolerant of atrioventricular dyssynchrony, acute rhythm control can be achieved either with electrical cardioversion or pharmacologically with antiarrhythmic medications.<sup>16,17,80,81,83,84</sup> Rhythm control should also be considered for patients unable to attain clinically adequate rate control despite optimal use of atrioventricular node-blocking agents and identification and management of acute triggers.

Real-world data demonstrate the safety and efficacy for both electrical cardioversion and pharmacological cardioversion in contemporary practice.<sup>83,85,86</sup> In patients with recent onset of AF, the RAFF2 study (Trial of Electrical Versus

Pharmacological Cardioversion for RAFF in the ED) demonstrated high success of restoration of sinus rhythm with either an upfront electrical cardioversion strategy or a stepwise strategy with initial pharmacological cardioversion and then DCCV if pharmacological cardioversion was unable to restore sinus rhythm (92% in the DCCV only group versus 96% in the medication/DCCV group;  $P=0.07$ ).<sup>87</sup>

### Antiarrhythmic Medications for Acute Pharmacological Cardioversion or Maintenance of Sinus Rhythm

Antiarrhythmic medications may be used for acute chemical cardioversion or maintenance of sinus rhythm. Choice of antiarrhythmic medication has to be tailored to the individual patient given the unique safety profiles of each agent.<sup>16,17</sup> In the appropriate population, ibutilide,<sup>16,88,89</sup> dofetilide,<sup>16,90</sup> flecainide,<sup>16,91</sup> propafenone,<sup>16,92</sup> amiodarone,<sup>16,93</sup> procainamide,<sup>87</sup> and vernakalant (not approved by the Food and Drug Administration for use in the United States)<sup>18,94</sup> are used for acute pharmacological cardioversion, typically with a more gradual time course for acute conversion to sinus rhythm noted with amiodarone<sup>16,93</sup> or dofetilide.<sup>90</sup> Supplemental Table 2 details the dosing and clinical considerations of antiarrhythmic medications for acute pharmacological cardioversion of AF. In general, the choice of agent depends on the individual situation and underlying clinical substrate such as cardiac and renal function. Ibutilide can be a reasonable choice for patients unable to receive anesthesia in the absence of existing QT prolongation. The most important concern is torsade de pointes, so the



patient must have a normal QTc interval. Ibutilide effects are short lasting (<4 hours); thus, it is not an ideal drug if recurrence of arrhythmia is expected. For patients able to take oral medications and without underlying structural heart disease, either propafenone or flecainide oral bolus is an option, with the advantage that they can be transitioned to ongoing dosing. Amiodarone also has the advantage of transitioning from intravenous to oral form, but cardioversion with amiodarone takes longer than with the aforementioned drugs. Because amiodarone may prolong the QT interval, the use of amiodarone may limit concomitant and subsequent pharmacological options given concerns for potentiation of QT prolongation. Procainamide is also an intravenous option for acute conversion of AF. While using intravenous procainamide, the patient needs to be closely monitored for hypotension, QT prolongation, and proarrhythmia. In the critical ill patient, electrical cardioversion is effective, but relapse is common<sup>95</sup>; similarly, relapse would likely be common after pharmacological cardioversion until the underlying acute illness subsides or adequate drug levels of rhythm control agent have been achieved.

### Electrical Cardioversion

Electrical cardioversion with DCCV has a high success rate for restoring sinus rhythm.<sup>96–101</sup> Electrical cardioversion is safe,<sup>85</sup> rapid, and more effective than pharmacological cardioversion alone,<sup>18,98,101</sup> with the tradeoff of the need for sedation with electrical cardioversion.<sup>18,102</sup> A patient's suitability for anesthesia and the ideal anesthesia regimen to support electrical cardioversion benefit from multidisciplinary considerations.

The efficacy of DCCV can be improved by use of biphasic energy<sup>103</sup> and upfront high fixed energy instead of a strategy of energy escalation.<sup>104</sup> Application of electrode pads in anterior-posterior orientation makes physiological sense for optimization of the vector for current delivery. Prior study of patients with persistent AF undergoing DCCV with escalation of energy found anterior-posterior orientation of the electrode vector more successful at restoring sinus rhythm than an anterior-lateral vector.<sup>105</sup> A subsequent study of patients with recently diagnosed AF undergoing DCCV using biphasic upfront 200 J found similar success rates with electrode vectors in either the anterior-posterior or anterior-lateral orientation.<sup>87</sup> These results together suggest that when the energy output is already optimized as biphasic and high energy and the AF is of recent onset, either vector orientation may be suitable.<sup>87</sup> However, when energy output is not high or when the AF is of longer duration, the anterior-posterior orientation may be more effective. In patients with a longer duration of AF, antiarrhythmic medications may also be administered as a pretreatment to facilitate electrical cardioversion.<sup>16,18,85,106</sup> In patients with obesity, the use of paddles, manual pressure augmentation, and further

escalation of electrical energy improved the success of electrical cardioversion.<sup>107</sup> In patients with failed initial electrical cardioversion, optimization of vector and energy delivery, manual pressure augmentation, and pretreatment with an antiarrhythmic can facilitate success of repeat electrical cardioversion.

### Monitoring During and After Cardioversion

Cardioversion with either an electrical or a pharmacological approach warrants electrocardiographic, hemodynamic, and oximetry monitoring during and after cardioversion.<sup>18,81</sup> Postcardioversion monitoring for pharmacological cardioversion is recommended for a duration of time that is equal to half of the therapeutic half-life of the medication,<sup>81</sup> and for electrical cardioversion with anesthesia, the duration of monitoring after electrical cardioversion would be as per usual postanesthesia monitoring for the extent of anesthesia necessary to support the performed electrical cardioversion. In patients who receive ibutilide, the most important concern is torsade de pointes, which usually occurs within 30 minutes of drug administration; nevertheless, close monitoring is required with a defibrillator readily available for 4 hours or until QT normalizes. Bradycardia is common after cardioversion because of sinus node suppression of automaticity. Bradycardia commonly improves after the patient wakes up and the sinus node recovers while in sinus rhythm; it is uncommon for severe bradycardia to require intervention other than drug dose adjustment in the rare instances that bradycardia fails to resolve. It is important to note that sinus node function can eventually normalize if the patient is able to maintain sinus rhythm.<sup>108</sup>

## Anticoagulation During Acute Hospitalization

### General Considerations

A decision to initiate anticoagulation needs to balance the risk of thromboembolism against the risk of bleeding and should involve shared decision-making with the patient. General considerations for anticoagulation for patients with AF are based on substrates, with CHA<sub>2</sub>DS<sub>2</sub>-VASc<sup>51</sup> score of ≥2 for men or ≥3 for women as an accepted indication for anticoagulation<sup>16–18</sup> in the absence of contraindications and significant bleeding risks. In the setting of acute illness, potential prothrombotic and coagulopathic milieu<sup>109–112</sup> and periprocedural hemostasis may also need to be considered. Once a decision for anticoagulation is made, the feasibility and timing for initiation of anticoagulation will likely depend on the context of the acute illness. Considerations in association with specific conditions are discussed further in a subsequent section (Acute Management Considerations in Specific Settings and Populations).

Whether incorporation of markers of prothrombotic potential and coagulopathic states<sup>109,110,112,113</sup> may

further refine the candidacy of patients with acute AF for anticoagulation is an important area for future research. Consistent with newly detected AF in general, there is uncertainty in the optimal threshold of AF burden to initiate anticoagulation.<sup>18,114,115</sup> Future research to better understand the optimal threshold of acute AF burden to initiate anticoagulation would be beneficial and clinically practical.

### **Thromboembolic Risks of Acute Cardioversion**

Thromboembolic risks in the setting of acute cardioversion are attributed to potential existing thrombus, a change in atrial mechanical function with restoration of sinus rhythm, atrial stunning after cardioversion, and a transient prothrombotic state.<sup>116,117</sup> Thromboembolic risks and considerations of anticoagulation apply to both pharmacological cardioversion and electrical cardioversion.<sup>118,119</sup>

Related to anticoagulation management in the setting of acute cardioversion, the prior concept of safe to cardiovert without further assessment or anticoagulation if AF duration has been no more than 48 hours has been challenged.<sup>17,18</sup> Subsequent study found time to cardioversion  $\geq 12$  hours to be an independent predictor of thromboembolic complications.<sup>120</sup> More recent data demonstrated that even when the reported duration of AF is no more than 48 hours, the thromboembolic risks were not homogeneously low but rather increased in patients with increasing CHA<sub>2</sub>DS<sub>2</sub>-VASc score.<sup>121–123</sup> Together, these findings suggest a more nuanced consideration of duration of AF (<12, 12–24, 24–48 hours) and patient-based risk factors (CHA<sub>2</sub>DS<sub>2</sub>-VASc score) in the pericardioversion management of the patient. When early cardioversion is planned, in the absence of 3 weeks of precardioversion anticoagulation with ascertainment of strict compliance or time in therapeutic window, a transesophageal echocardiogram to exclude existing intracardiac thrombus before cardioversion is recommended by current guidelines.<sup>17,18</sup> Cardiac computed tomography, especially with delayed contrast-enhanced image acquisition protocol, has emerged as an alternative imaging modality to exclude intracardiac thrombus.<sup>124–126</sup> Anticoagulation is recommended to be initiated as soon as possible before AF cardioversion.<sup>17,18</sup> When intracardiac thrombus is excluded, cardioversion may proceed with the patient on therapeutic anticoagulation.<sup>127,128</sup>

After cardioversion, uninterrupted anticoagulation is recommended for 4 weeks,<sup>16–18</sup> the putative period for recovery of mechanical atrial systole. Only in patients with CHA<sub>2</sub>DS<sub>2</sub>-VASc of 0 in men or 1 in women with very low associated thromboembolic risks<sup>21,122</sup> may omission of such uninterrupted postcardioversion anticoagulation be considered.<sup>17,18</sup> Thus, the decision to cardiovert a hemodynamically stable patient with acute AF should include care team discussions and patient counseling of anticoagulation compliance over the 4 weeks after acute

cardioversion without anticipated interruptions, for example, as related to upcoming procedural needs. If interruption of anticoagulation is anticipated in a hemodynamically stable patient with acute AF, a focus on rate control first and deferring cardioversion until no further interruption of anticoagulation is anticipated may be preferable.

### **Options for Anticoagulation During Acute Hospitalization**

There are parenteral and oral options for anticoagulation during acute hospitalization. Dosing and considerations are summarized in [Supplemental Tables 3 and 4](#), respectively. Given rapid time to therapeutic efficacy and ease of continuation, direct oral anticoagulants (DOACs) have been recommended for thromboembolic prophylaxis including in the setting of cardioversion for AF, barring contraindications.<sup>17,18</sup> Post hoc analyses of the pivotal phase III studies comparing DOACs with warfarin for anticoagulation of nonvalvular AF and subsequent dedicated prospective trials specifically related to cardioversion support the efficacy of DOACs for thromboembolic prophylaxis in the setting of cardioversion.<sup>129–136</sup> Strategies to manage potential bleeding and availability and access to reversal or mitigating agents should also be part of the consideration in deciding on the choice of anticoagulant.

## **Acute Management Considerations in Specific Settings and Populations**

### **In the Setting of the Emergency Department**

The ED is frequently the first point of diagnosis and management of acute AF. Subsequent management of acute AF may occur as part of an acute hospitalization or in an observation unit.<sup>137</sup> Emergency presentation of hemodynamically unstable acute AF is managed with immediate DCCV. Assessment of acute AF in hemodynamically stable patients in the ED includes determination of concomitant medical or surgical processes as potential triggers and initiation of multidisciplinary management. The decision for rate or rhythm control mirrors the inpatient setting, and these approaches are not mutually exclusive. Rate control is often initiated early in the ED course; rhythm control may be subsequently undertaken. Initiation of anticoagulation in the ED is safe.<sup>138</sup> Considerations for anticoagulation include not only substrate-based assessment for thromboembolic risks (such as through the use of the CHA<sub>2</sub>DS<sub>2</sub>-VASc score<sup>51</sup>) but also assessment of active bleeding risks or contraindications.<sup>139</sup> Evaluation of an anticipated need for interruption of anticoagulation, in the near future or as part of necessary procedural management of concomitant processes, may also influence candidacy for acute cardioversion in hemodynamically stable patients with acute AF. Transesophageal echocardiography may be performed to assess for left atrial or appendage

thrombus before cardioversion, as discussed above.<sup>128</sup> This is particularly important for patients without anticoagulant therapy or those uncertain of compliance with anticoagulant or time in target range on warfarin. Antiarrhythmic medications may be administered to facilitate rhythm conversion before DCCV and to maintain sinus rhythm after DCCV.<sup>16,18,85,106</sup>

### **In Critically Ill Patients**

Aggressive management of acute illnesses and prompt treatment of triggers remain the cornerstone of acute AF management in critically ill patients.<sup>2,81</sup> It may be appropriate to wait to directly treat the acute AF until further treatment of the acute illness if the rapid heart rate is a compensatory mechanism for the critical illness.<sup>2</sup> In patient whose acute AF is causing hemodynamic compromise, immediate DCCV is the strategy of choice.<sup>18,82</sup> In the absence of hemodynamic compromise, both rate and rhythm control strategies may be considered.<sup>81</sup> Electrical cardioversion may be successful, but early relapse is common in patients who remain acutely ill.<sup>95</sup> Amiodarone and propafenone have demonstrated efficacy for pharmacological cardioversion in this population.<sup>140</sup> Prior limited studies suggest that for acute AF in the critically ill, metoprolol may provide better rate control compared with diltiazem<sup>141</sup> and that esmolol use may be associated with improved arterial elastance<sup>142</sup> and reduced short-term mortality.<sup>143,144</sup> Although the reduction of in-hospital mortality with  $\beta$ -blockade was no longer evident after multivariable adjustment reflective of more favorable hemodynamic profile before initiation of  $\beta$ -blockade, when feasible,  $\beta$ -blockade remains a reasonable choice for rate control given its demonstrated efficacy in this regard.<sup>145</sup>

Critically ill patients with new-onset AF have a >2-fold higher risk of in-hospital ischemic stroke compared with those without AF.<sup>21</sup> In patients with sepsis, however, CHA<sub>2</sub>DS<sub>2</sub>-VASc alone poorly predicts the risk for ischemic stroke.<sup>146</sup> Parenteral anticoagulation in patients with acute AF and sepsis did not reduce risks for ischemic stroke<sup>146,147</sup> and was associated with increased clinically significant bleeding in one study.<sup>146</sup> Available evidence does not favor routine acute anticoagulation in patients with sepsis with acute AF. Further research combining risk scores based predominantly on chronic conditions (such as the CHA<sub>2</sub>DS<sub>2</sub>-VASc risk score) with considerations of the acute coagulopathic<sup>112</sup> and prothrombotic<sup>148</sup> milieu may be useful to better assess the benefits, risks, and optimal selection of critically ill patients with acute AF for acute anticoagulation.

### **Coronavirus Disease 2019**

Similar to critical illness in general, AF in the setting of coronavirus disease 2019 (COVID-19) is related to disease severity.<sup>149,150</sup> The first wave of COVID-19 in particular, however, has been associated with thrombotic events, especially among those with greater

illness severity.<sup>151</sup> Preadmission oral anticoagulation in patients with preexisting AF with COVID-19 was associated with a lower likelihood of adverse events during the hospitalization.<sup>152</sup> Broader data on thromboprophylaxis in COVID-19<sup>153–156</sup> may offer additional insights into the consideration of thrombotic states and choices for potential anticoagulation. Whether the propensity for thrombosis or benefits of anticoagulation would remain applicable to the subsequent variants of the COVID-19 pandemic or to individuals who have received vaccines and boosters needs to be further assessed.

### **Hyperthyroidism**

Goals for management of acute AF in the setting of hyperthyroidism include efforts to restore the euthyroid state and, if feasible,  $\beta$ -blockade for rate control.<sup>16</sup> Although hyperthyroidism may induce a hematologically prothrombotic state, with an increase in factors VIII and IX, fibrinogen, von Willebrand factor, and plasminogen activator inhibitor-1,<sup>157</sup> hyperthyroidism is not included in the risk stratification scheme for thromboembolism in patients with AF.<sup>51</sup> Correlation of hyperthyroidism with clinical thromboembolism has been controversial; anticoagulation for patients with thyrotoxicosis and AF is guided by CHA<sub>2</sub>DS<sub>2</sub>-VASc risk factors in the 2014 American Heart Association/American College of Cardiology/Heart Rhythm Society guideline on the management of AF.<sup>16</sup> Recent data noted increased risks of ischemic stroke and systemic embolism in patients with AF with hyperthyroidism in the first year of AF diagnosis but with a reduction of increased risks with treatment of hyperthyroidism.<sup>158</sup> These nuanced data underscore the importance of treating the hyperthyroidism and may prompt additional consideration for anticoagulation while attempting to restore the euthyroid state during the first year of AF diagnosis.

### **Stroke**

The temporal relationship between AF and stroke is complex.<sup>159–164</sup> Diagnosis of AF during acute hospitalization for stroke may also represent detection of previously unrecognized AF (consistent with one of the outlined pathways of acute AF in Figure 2). Broad consideration of the temporal relationship between AF and stroke is beyond the scope of this scientific statement. However, pertinent to this scientific statement are the observations that a subset of AF can manifest in temporal proximity to stroke events<sup>159,160,164,165</sup> and that sometimes first diagnosis of AF may occur in close temporal proximity to incident stroke,<sup>165</sup> posing implications for clinical management and the timing of anticoagulation. Approximately 6.5% to 15% of strokes occur in hospitalized patients, and stroke is more common in the perioperative setting and in patients with high-risk conditions such as acute coronary syndromes or prothrombotic states.<sup>166</sup> Strokes



associated with AF more commonly involve the middle cerebral artery territories (much less commonly the vertebrobasilar territories) and may be amenable to mechanical thrombectomy.<sup>167</sup> In general, the risk of early re-embolization is low.<sup>168</sup> Urgent anticoagulation with the goal of preventing early recurrent stroke or preventing neurological deterioration is not recommended.<sup>169</sup> Because of the low risk of early recurrent stroke and the risk of worsening hemorrhagic transformation, it is reasonable to delay oral anticoagulation for 4 to 14 days among those with acute ischemic stroke in the setting of AF.<sup>169</sup> Ongoing RCTs (ELAN [Early Versus Late Initiation of Direct Oral Anticoagulants in Post-Ischaemic Stroke Patients With Atrial Fibrillation; NCT03148457], OPTIMAS [Optimal Timing of Anticoagulation After Acute Ischaemic Stroke; NCT03759938], TIMING [Timing of Oral Anticoagulant Therapy in Acute Ischemic Stroke With Atrial Fibrillation; NCT02961348], and START [Optimal Delay Time to Initiate Anticoagulation After Ischemic Stroke in Atrial Fibrillation; NCT03021928]) will specifically assess early versus late initiation of anticoagulation using DOACs in patients with AF-related ischemic stroke. Issues related to the long-term use of oral anticoagulants are addressed in other guidelines.<sup>17,170</sup>

### Noncardiac Surgery

The treatment of AF after noncardiac surgery should include the identification and correction of potential triggers and sources of triggers (Figure 1).<sup>171</sup> Of particular importance is the exclusion of bleeding, which would influence the overall management of a patient's acute AF after noncardiac surgery. Adrenergic surge, volume loss, inflammation, and shifts in autonomic tone in the setting of bleeding may contribute as triggers, and tachycardia may be compensatory for acute blood loss. Ongoing bleed would preclude initiation of anticoagulation necessary for rhythm control strategy.

Given that AF after noncardiac surgery frequently spontaneously reverts to sinus rhythm,<sup>172</sup> it may be reasonable to treat AF after noncardiac surgery with a rate control strategy when the tachycardia is not a compensatory response for acute volume loss and underlying triggers have been identified and aggressively treated. A rhythm control strategy may be considered for selected patients who remain symptomatic despite rate control or in whom rapid restoration of sinus rhythm may be preferred given comorbidities such as heart failure or severe ischemia.<sup>173</sup> Anticoagulation indication is balanced by the need for surgical hemostasis. Therefore, safety, feasibility, and the timing of initiation of acute anticoagulation warrant close discussions with the care teams involved in the specific surgery. Multidisciplinary discussion should include individualized considerations of intraprocedural bleeding, adequacy of surgical hemostasis at the end of the surgery, likelihood for rebleed or susceptibility to

surgical site bleeding on anticoagulant challenge, and potential ramifications of bleed (particularly debilitating in circumstances such as spinal surgery).

### Cardiac Surgery

#### Prophylaxis for AF After Cardiac Surgery

In recognition of the high prevalence and associated adverse outcomes of postoperative AF in the setting of cardiac surgery,<sup>9,11,12</sup> prophylactic treatments are recommended by society guidelines.<sup>16,18,174</sup>  $\beta$ -Blockade and amiodarone are currently the agents of choice for pharmacological prophylaxis for postoperative AF in the setting of cardiac surgery.<sup>18</sup> Data based on small studies, predominantly demonstrating efficacy of  $\beta$ -blockade in reducing postoperative AF in isolation or in combination with amiodarone,<sup>175–177</sup> have led to preoperative  $\beta$ -blockade as a quality metric.<sup>176</sup> However, preoperative  $\beta$ -blockade within 24 hours of isolated coronary artery bypass surgery as a quality measure has been challenged<sup>176</sup>; a study of 140 000 propensity-matched individuals from the Society of Thoracic Surgeons database found  $\beta$ -blockade to be associated with a small but finite increase in the rate of postoperative AF without a reduction of morbidities or mortality.<sup>178</sup> It is not clear whether evaluation of more gradual administration of  $\beta$ -blockade upstream instead of within the 24-hour perioperative window or the inclusion of patients with concomitant valvular surgery who have even higher risks for postoperative AF may be differentially associated with outcomes. Amiodarone is the most universally accepted antiarrhythmic agent used for the prevention of AF after cardiac surgery. Its efficacy was initially demonstrated in 1997 with a small, double-blind, placebo-controlled, randomized study encompassing 124 patients.<sup>179</sup> Subsequent small studies have consistently shown its efficacy in both oral and intravenous form.<sup>180</sup> Because of its side-effect profile, it is typically reserved for patients at high risk for postoperative AF. Consistent with this, a multinational survey of cardiac anesthesiologists demonstrated limited use of amiodarone as prophylaxis for postoperative AF, citing concerns for risks related to the side-effect profile of amiodarone.<sup>66</sup>

In terms of colchicine, although the AF substudy of the COPPS study (Colchicine for the Prevention of the Postpericardiotomy Syndrome) demonstrated a reduction of postoperative AF and length of stay,<sup>181</sup> leading to inclusion in the 2014 American Heart Association/American College of Cardiology/Heart Rhythm Society guideline as a IIb recommendation,<sup>16</sup> the subsequent COPPS-2 study (Colchicine for Prevention of Postpericardiotomy Syndrome and Postoperative Atrial Fibrillation)<sup>182</sup> and END-AF study (Effect of Colchicine on the Incidence of Atrial Fibrillation in Open Heart Surgery Patients)<sup>183</sup> did not demonstrate statistically significant

reductions of postoperative AF during hospitalization after cardiac surgery, and associated diarrhea led to discontinuation of colchicine in more than half of colchicine recipients.<sup>183</sup> Recent comprehensive guidelines<sup>18</sup> noted data for colchicine as pharmacological prophylaxis for postoperative AF in the setting of cardiac surgery not to be robust. Other agents such as renin-angiotensin system inhibitors, nonsteroidal anti-inflammatory agents, steroids, statins, omega-3 fatty acids in the form of fish oil supplements, calcium channel blockers, digitalis, and angiotensin-converting enzyme inhibitors have been tested in small-scale clinical trials, showing varying efficacy in prophylaxis for AF after cardiac surgery.

Notable updates in this arena include further considerations of pericardiotomy and botulinum toxin for the prophylaxis of AF after cardiac surgery. The recently published prospective, single-center, randomized PALACS study (Posterior Left Pericardiotomy for the Prevention of Atrial Fibrillation After Cardiac Surgery) found posterior left pericardiotomy to be associated with a reduction in the incidence of postoperative AF in selective patients undergoing coronary bypass or aortic valve or aortic surgery without significantly added risks.<sup>184</sup> The phase 2 multicenter, randomized NOVA study (Neurotoxin [Botulinum Toxin Type A] for the Prevention of Post-Operative Atrial Fibrillation)<sup>185</sup> completed its recruitment in December 2021. Future studies may further assess the clinical utility and implementation feasibility of these potentially promising modalities.

### Acute Treatment of AF After Cardiac Surgery

Treating hemodynamically stable, asymptomatic, acute AF after cardiac surgery with rate control as the initial strategy is reasonable<sup>18</sup> given the similar length of hospitalization, morbidities, and mortality with a rate control target of <100 bpm or rhythm maintenance with amiodarone.<sup>42</sup> When acute pharmacological cardioversion is considered, ibutilide<sup>16,89</sup> and vernakalant (not approved by the US Food and Drug Administration for use in the United States)<sup>18,94</sup> have demonstrated specific efficacy in acute pharmacological cardioversion of AF after cardiac surgery.

Special consideration should be given to patients who develop atrial arrhythmias after surgical ablation, which may vary in extent of ablation lesion sets.<sup>186</sup> Management of this specific population would benefit from a heart team approach<sup>187</sup> with close collaboration of the cardiac electrophysiologist and the operating surgeon in further individualizing acute treatment strategies and plans for longer-term<sup>188</sup> follow-up. Acute management strategies will need to take into account potential concomitant sinus node dysfunction and an early period of extensive atrial inflammation.


### Acute Anticoagulation Considerations for AF After Cardiac Surgery

Data related to anticoagulation for AF after cardiac surgery are limited. Balancing the risk of stroke in

this vulnerable population against the risk of major bleeding in this postsurgical population is key. Retrospective studies have highlighted the association of AF after isolated coronary artery bypass surgery with increased adverse outcomes of ischemic stroke and thromboembolism<sup>35,40</sup> and mortality<sup>35,41</sup> but have shown conflicting results in terms of the potential benefit of early initiation of oral anticoagulation.<sup>40,41</sup> The conflicting results may relate to the nonrandomized nature of oral anticoagulant treatment; recipients of oral anticoagulants may be older, more frequently have a history of heart failure,<sup>40</sup> and have increased risks for both thromboembolic and bleeding complications. Furthermore, although the retrospective studies included populations who had undergone cardioversion,<sup>40,41</sup> the timing of anticoagulation in relation to the cardioversion was unclear.

In the absence of data from dedicated RCTs in this regard, the anticoagulation protocol used in the Cardiothoracic Surgical Trials Network RCT on rate versus rhythm control<sup>42</sup> has frequently been extrapolated for clinical care. The study protocol recommended anticoagulation if patients remained in AF or had recurrent AF 48 hours after study randomization; anticoagulation with warfarin targeting an international normalized ratio of 2 to 3 was recommended, and bridging with low-molecular-weight heparin was allowed.<sup>42</sup> Anticoagulation was recommended to be continued for 60 days unless complications occurred.<sup>42</sup> However, it is important to note that the Cardiothoracic Surgical Trials Network RCT on rate versus rhythm control was focused primarily on rate versus rhythm control and was not powered to detect thromboembolism and stroke. Recognizing this gap in knowledge in clinical practice, the ongoing randomized PACES (Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG study; NCT04045665) will provide specific insights in this regard.

For patients after surgical ablation for AF, the current guideline recommends oral anticoagulation as soon as feasible given endothelial disruption during ablation while balancing the risk of postoperative bleeding.<sup>18</sup> One recent development has been the addition of left atrial appendage ligation at the time of cardiac surgery to reduce the risk of stroke in patients with a history of AF. LAAOS III (Left Atrial Appendage Occlusion Study III) demonstrated that concomitant left atrial appendage occlusion performed during cardiac surgery in patients with prior AF and a high CHA<sub>2</sub>DS<sub>2</sub>-VASc score (mean, 4.2) continued on long-term oral anticoagulation over follow-up significantly reduced stroke and thromboembolism risk over a follow-up of 3.8 years (4.8% in the occlusion group versus 7.0% in the no-occlusion group; hazard ratio, 0.67 [95% CI, 0.53–0.85; *P*=0.001]).<sup>189</sup> Because of this study, there has been growing enthusiasm for broader clinical implementation. Although modern techniques



**Figure 4. Care pathway for acute AF.**

AF indicates atrial fibrillation; and EP, cardiac electrophysiology.

for surgical left atrial appendage have improved the success of closure,<sup>190</sup> given the potential for incomplete ligation,<sup>190–192</sup> management of postoperative AF in patients with reported left atrial appendage closure include formal evaluation of the left atrial appendage with transesophageal echocardiogram or computed tomography to assess for adequacy of closure.

### Atrial Flutter

Management of atrial flutter in the acute care setting follows the same principles as AF management. Often, atrial flutter is more difficult than AF to rate control medically, necessitating cardioversion for patients with atrial flutter. Although most studies on electrical cardioversion were performed on patients with AF, the same principles concerning precardioversion and postcardioversion anticoagulation apply (see the Thromboembolic Risks of Acute Cardioversion section). For medical cardioversion of atrial flutter, ibutilide and dofetilide have been shown to be more effective than the class I medications<sup>193–195</sup> or intravenous amiodarone.<sup>196,197</sup> The class I medications can also have the untoward effect of slowing the flutter cycle length, resulting in rapid ventricular rates from 1:1 atrioventricular conduction of atrial flutter if conversion is not achieved.<sup>198,199</sup> Ablation for typical atrial flutter in the acute setting may also be considered given its excellent success rate,<sup>200–202</sup> although patient risk factors and concurrent acute illnesses may necessitate medical optimization before they are considered good ablation candidates. Because up to 50% of patients with atrial flutter can be found to have incident AF after atrial flutter,<sup>203</sup> long-term AF surveillance monitoring is prudent after treatment for atrial flutter.

## LONGER-TERM MANAGEMENT

For patients with acute AF, patient counseling about the risk of recurrent AF after the acute illness is resolved and access to follow-up care are important aspects of discharge planning (Figure 4).

### Acute AF Recurs Long Term

Patients with acute AF in the setting of acute medical illness<sup>1,2,15</sup> and noncardiac<sup>3–6</sup> and cardiac<sup>8,9,11–14</sup> surgeries have high rates of AF recurrence long term. The 5-year AF recurrence rates were 42% to 68%,<sup>1,4</sup> 39%,<sup>7</sup> and 32% to 76%<sup>4,8–10</sup> in patients with acute AF in the setting of acute medical illness,<sup>1,4</sup> noncardiac surgeries,<sup>7</sup> cardiac surgeries,<sup>8,9,11–14</sup> respectively, with higher detection of recurrence in studies using continuous heart rhythm monitoring.<sup>8–10</sup>

### Long-Term Follow-Up Care

Given the notable long-term AF recurrence, patients with acute AF warrant long-term outpatient follow-up evaluation and management. In patients with newly diagnosed AF from the Veterans Health Administration, receipt of cardiology care versus only primary care was associated with a reduction of stroke and death, potentially mediated by early prescription of oral anticoagulant therapy.<sup>204</sup> Clinical follow-up evaluation with the cardiovascular specialist include assessment of family history, associated conditions and risk factors, structural heart disease, thromboembolic risk, and symptoms.<sup>16</sup> Further management of AF, anticoagulation, and considerations for monitoring and guidance on appropriate risk factor modification are key aspects of long-term

management of patients with acute AF (Figure 4). The rise of telehealth has the potential to increase access to cardiovascular specialists for patients in rural and underserved areas. AF diagnosis, evaluation, and management are well suited for telemedicine when paired with mobile technology for the assessment of heart rate and rhythm.<sup>205,206</sup>

## Options and Strategies for Heart Rhythm Monitoring

Follow-up heart rhythm monitoring is prudent because recurrent AF may be asymptomatic or may not be reliably identified by symptoms. Heart rhythm monitoring may further inform individualized shared decision-making and guide AF management strategies in conjunction with ongoing cardiovascular follow-up and assessment. Clinical monitoring modalities include 12-lead ECG (seconds), Holter (hours to days), continuous ambulatory monitoring patches (days to weeks), event monitors (multiple weeks), and implantable loop recorders (years).<sup>206</sup> Potential incorporation of direct-to-consumer mobile health technologies into the clinical arena is an area of active research.<sup>206,207</sup>

Different monitoring strategies have been used to identify long-term recurrence of AF in patients who had acute AF during hospitalization. Among observational studies of patients with acute AF after cardiac surgery, higher detection rates of recurrent AF were reported in studies that used continuous longer-term monitoring.<sup>8–10</sup> Although no RCT has specifically compared different monitoring strategies for outpatient follow-up of patients with acute AF during hospitalization, insights may be drawn from trials that compared different monitoring strategies in clinical populations for the purpose of identifying AF. The CRYSTAL-AF RCT (Cryptogenic Stroke and Underlying AF)<sup>207a</sup> and SEARCH-AF RCT (Detection of Atrial Fibrillation After Cardiac Surgery)<sup>208</sup> assessed the comparative detection of an implantable cardiac monitor versus usual outpatient follow-up care in poststroke and post-cardiac surgery patients, respectively, predominantly without in-hospital detection of AF (SEARCH-AF<sup>208</sup> included a small number of patients who had AF lasting <24 hours after cardiac surgery). Both studies demonstrated increased sensitivity for the detection of AF with longer-term continuous monitoring such as with an implantable cardiac monitor compared with usual care.

In the absence of RCTs of monitoring strategies specific to acute AF, we suggest shared decision-making with consideration of patient substrate for AF and thromboembolic risks in the selection of the monitoring strategy. Given the high risk for AF recurrence in patients with acute AF across medical and surgical acute conditions, patients with acute AF with a CHA<sub>2</sub>DS<sub>2</sub>-VASc score of  $\geq 2$  for men or  $\geq 3$  for women,


an accepted threshold of increased annual risk of stroke, may warrant longer duration of monitoring, and consideration of longer-term continuous monitoring strategy may be reasonable. A conceptual illustration to consider increasing intensity of heart rhythm monitoring in patients with substrates for elevated thromboembolic risks and AF recurrence is shown in Figure 4. The optimal frequency, duration, and modality of long-term monitoring for patients with acute AF remain unclear and need further research to guide care in this population with high long-term AF recurrence risks.

## Considerations for Long-Term Anticoagulation

The decision to pursue longer-term anticoagulation is based on patient substrate and thromboembolic risk barring contraindications to anticoagulation. Retrospective registry data suggest similar long-term thromboembolic risks in patients with AF with and without acute triggers precipitating manifestation of AF.<sup>6,209</sup> Given the high rates of long-term AF recurrence after acute AF episodes,<sup>1–13,15</sup> barring significant contraindications, initiation of long-term anticoagulation according to the patient's stroke risk similar to the general approach for long-term anticoagulation in patients with AF may be reasonable. Current guidelines recommend long-term anticoagulation for patients with a CHA<sub>2</sub>DS<sub>2</sub>-VASc score of  $\geq 2$  for men or  $\geq 3$  for women, with preference for DOAC over vitamin K antagonist.<sup>17,18</sup> Dosing, pharmacological properties, and additional considerations of the oral anticoagulants are summarized in [Supplemental Table 4](#). For patients who have undergone cardioversion as part of the management of acute AF, anticoagulation should not be interrupted during the 4 weeks after cardioversion due to concerns for thromboembolism and atrial stunning.<sup>17,18</sup> Decisions for further anticoagulation beyond the 4 weeks after cardioversion should be guided by substrate. In patients with high thromboembolic risk (such as those with high CHA<sub>2</sub>DS<sub>2</sub>-VASc scores or equivalent), continuation of anticoagulation, barring contraindications, may be reasonable because acute AF may be a manifestation of previously undiagnosed and likely recurrent AF.

Currently, for patients with acute AF after cardiac surgery, long-term anticoagulation may be considered according to the anticipated net benefit and informed patient preference. Results from the ongoing prospective, randomized PACES will provide some guidance based on results from randomization to oral anticoagulant plus background antiplatelet therapy (versus antiplatelet only) for the protocol duration of 90 days. For patients who underwent surgical AF ablation, oral anticoagulation as soon as feasible during hospitalization and long-term anticoagulation based on CHA<sub>2</sub>DS<sub>2</sub>-VASc score are recommended.<sup>18</sup> Follow-up of patients with AF after cardiac surgery with reported left atrial





**Figure 5. Summary of management of acute AF.**  
AF indicates atrial fibrillation.

appendage closure warrants evaluation of the left atrial appendage with transesophageal echocardiogram or computed tomography to assess for adequacy of closure and further consideration for anticoagulation based on adequacy of closure as well as additional assessment of the patient's thromboembolic risk.

In patients who developed acute AF after noncardiac surgery, registry data suggest that initiation of oral anticoagulation within 30 days after discharge was associated with a reduced risk of thromboembolic events.<sup>6</sup> The randomized prospective ASPIRE-AF trial (Anticoagulation for Stroke Prevention In Patients With Recent Episodes of Perioperative Atrial Fibrillation After Noncardiac Surgery; NCT03968393) will further inform the optimal long-term oral anticoagulation strategy for patients who develop acute AF after noncardiac surgery.

Longer-Term Rhythm Management

Long-term rhythm management should be individualized as part of a shared decision plan with each patient. In EAST-AFNET 4 (Early Treatment of Atrial Fibrillation for Stroke Prevention Trial), an early rhythm control strategy within 1 year of AF diagnosis was associated with a lower risk of adverse cardiovascular outcomes.<sup>210</sup> Whether this benefit extends to AF initially detected in the acute care setting merits further research.

The choice of rhythm control method is based on the balance of multiple factors, including patient preference, risk factors, and comorbidities. Long-term antiarrhythmic medication options are described in [Supplemental Table 5](#). The choice of antiarrhythmic drug is guided by patient baseline comorbidities and potential drug-drug interactions. Once any antiarrhythmic medication has been initiated, long-term monitoring is required to

**Table 1. Acute AF: 10 Key Implications for Clinical Practice**

10 Key Takeaways	
1	Acute AF is defined as AF detected in the setting of acute care or acute illness; this includes AF occurring during acute hospitalization. Acute AF may be detected or managed for the first time during acute hospitalization for another condition.
2	Acute AF is associated with high risk of long-term AF recurrence, warranting clinical attention during acute hospitalization, at transition of care, and over long-term follow-up.
3	A framework of substrates and triggers can be useful for the evaluation and management of AF occurring during acute hospitalization. AF after cardiac surgery is a distinct type of acute AF.
4	Acute management of AF occurring during hospitalization requires a multipronged approach. Key components of acute management include identification and treatment of triggers, selection and implementation of rate/rhythm control, and management of anticoagulation.
5	Acute rate or rhythm control strategy should be individualized with consideration of the patient's capacity to tolerate the potential rapid rates or atrioventricular dyssynchrony, as well as the patient's ability to tolerate the risk of either the rate or rhythm control strategy.
6	In hemodynamically unstable patients, immediate electrical cardioversion with DCCV is the treatment of choice. Rhythm control should also be considered for patients unable to attain clinically adequate rate control despite optimal use of atrioventricular nodal blocking agents and management of acute triggers. Electrical cardioversion is the most effective method to achieve acute rhythm control. Hemodynamic monitoring and considerations for thromboembolic prophylaxis are warranted for both electrical and pharmacological cardioversion.
7	Indication for anticoagulation is based on substrate, with feasibility and timing for anticoagulation based on patient's bleeding risk and contextual considerations of the acute conditions.
8	Given the high risks of AF recurrence in patients with acute AF, clinical follow-up and extended heart rhythm monitoring are warranted to tailor longer-term management. Management of AF and modifications targeting the substrate should be instituted. Long-term management will be heavily tied to the substrate, guiding follow-up, long-term heart rhythm monitoring, and considerations for rhythm management strategies.
9	Overall management of acute AF addresses substrates and triggers. The 3As of acute management are acute triggers, AF rate/rhythm management, and anticoagulation. The 2As and 2Ms of long-term management are AF rate/rhythm management, anticoagulation, monitoring of heart rhythm, and modification of lifestyle and risk factors.
10	Patients with acute AF benefit from close interdisciplinary care collaborations, allowing appropriate treatments tailored to patient's underlying substrates and acute conditions.

AF indicates atrial fibrillation; and DCCV, direct current cardioversion.

**Table 2. Areas for Future Research in Acute AF**

Aspect of acute AF	Area for future research
Detection	Patients at higher risk for acute AF may benefit from increased intensity of electrocardiographic monitoring during hospitalization. Developing a framework to triage the intensity of electrocardiographic monitoring during acute hospitalization is a practical area for future research.
Burden	Consistent with the current uncertainty in the optimal threshold of AF burden to initiate anticoagulation, further research is needed to identify the optimal threshold of the burden of acute AF to initiate anticoagulation in the acute setting.
Substrates and triggers	Using the conceptual framework of substrates and triggers, additional research in better understanding the substrates and triggers of acute AF in different acute conditions will further improve condition-specific considerations and treatments.
Specific risks	Additional dedicated studies of large cohorts are needed to better understand the acute thromboembolic risks of acute AF, in association with specific populations as pertinent, to provide condition-specific insights to further refine the candidacy and threshold for acute anticoagulation.
Acute milieu	Further research combining risk scores based predominantly on chronic conditions (such as the CHA <sub>2</sub> DS <sub>2</sub> -VASc risk score) with considerations of the acute coagulopathic and prothrombotic milieu may be useful to better assess the benefits, risks, and optimal selection of patients with acute AF for acute anticoagulation.
Long term	Given the high rates of long-term AF recurrence, the optimal frequency and modality of long-term monitoring in patients who have experienced acute AF need further study.

observe for potential toxicities. The potential toxicities and monitoring strategies are described in [Supplemental Table 5](#).

Several randomized trials have shown that AF ablation is more effective at maintaining long-term sinus rhythm compared with medical therapy.<sup>211,212</sup> Mortality benefit with AF ablation has been observed in patients with heart failure.<sup>213,214</sup> Over long-term management, in applicable patients, ablation may be considered as an early management strategy at experienced centers.<sup>17,18</sup>

### Longer-Term Adjunct Risk Factor Evaluation and Modifications

Obesity,<sup>215–217</sup> obstructive sleep apnea,<sup>218,219</sup> hypertension,<sup>220</sup> diabetes,<sup>221</sup> physical inactivity,<sup>222,223</sup> and alcohol abuse<sup>224–226</sup> have been shown to be risk factors for AF. Intensive weight loss,<sup>227</sup> comprehensive risk factor modifications (with weight loss, blood pressure management, glycemic control, sleep-disordered breathing management, alcohol reduction, and tobacco cessation counseling),<sup>228,229</sup> and aerobic exercise training<sup>230,231</sup> have been demonstrated to reduce AF burden and to improve quality of life.<sup>227–232</sup> Aggressive risk factor modification and lifestyle interventions<sup>18,233</sup> should be pursued for all patients with acute AF, in tandem with long-term AF management strategies.

## IMPLICATIONS FOR CLINICAL PRACTICE AND FURTHER RESEARCH

Table 1 delineates the Writing Committee's consensus for implications for clinical practice. In addition, the Writing Committee has outlined the current gaps in knowledge and areas for future research in acute AF in Table 2.

## CONCLUSIONS

Acute AF is defined as AF detected in the setting of acute care or acute illness. Acute AF may be detected or managed for the first time during acute hospitalization for another condition (Figure 2). Acute AF is common and not benign. Acute AF is associated with high risks of long-term AF recurrence, warranting clinical attention during acute hospitalization and over long-term follow-up (Figure 4). A conceptual framework of substrates and triggers can be useful for considering AF occurring during acute hospitalization. Overall management of acute AF addresses substrates and triggers. The 3As of acute management are acute triggers, AF rate/rhythm management, and anticoagulation (Figure 5). The 2As and 2Ms of long-term management include monitoring of heart rhythm and modification of lifestyle and risk factors, in addition to considerations for AF rate/rhythm management and anticoagulation (Figure 5). Several gaps in knowledge related to acute AF exist and warrant future research.

## ARTICLE INFORMATION

The American Heart Association makes every effort to avoid any actual or potential conflicts of interest that may arise as a result of an outside relationship or a personal, professional, or business interest of a member of the writing panel. Specifically, all members of the writing group are required to complete and submit a Disclosure Questionnaire showing all such relationships that might be perceived as real or potential conflicts of interest.

This statement was approved by the American Heart Association Science Advisory and Coordinating Committee on October 25, 2022, and the American Heart Association Executive Committee on January 24, 2023. A copy of the document is available at <https://professional.heart.org/statements> by using either "Search for Guidelines & Statements" or the "Browse by Topic" area. To purchase additional reprints, call 215-356-2721 or email [Meredith.Edelman@wolterskluwer.com](mailto:Meredith.Edelman@wolterskluwer.com).

The American Heart Association requests that this document be cited as follows: Chyou JY, Barkoudah E, Dukes JW, Goldstein LB, Joglar JA, Lee AM, Lubitz SA, Marill KA, Sneed KB, Streur MM, Wong GC, Gopinathannair R; on behalf of the American Heart Association Acute Cardiac Care and General Cardiology Committee, Electrophysiology and Arrhythmias Committee, and Clinical Pharmacology Committee of the Council on Clinical Cardiology; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation; Council on Cardiovascular and Stroke Nursing; and Stroke Council. Atrial fibrillation occurring during acute hospitalization: a scientific statement from the American Heart Association. *Circulation*. 2023;147:e676–e698. doi: 10.1161/CIR.0000000000001133

The expert peer review of AHA-commissioned documents (eg, scientific statements, clinical practice guidelines, systematic reviews) is conducted by the AHA Office of Science Operations. For more on AHA statements and guidelines development, visit <https://professional.heart.org/statements>. Select the "Guidelines & Statements" drop-down menu, then click "Publication Development."

Permissions: Multiple copies, modification, alteration, enhancement, and distribution of this document are not permitted without the express permission of the American Heart Association. Instructions for obtaining permission are located at <https://www.heart.org/permissions>. A link to the "Copyright Permissions Request Form" appears in the second paragraph (<https://www.heart.org/en/about-us/statements-and-policies/copyright-request-form>).

## Disclosures

## Writing Group Disclosures

Writing group member	Employment	Research grant	Other research support	Speakers' bureau/honoraria	Expert witness	Ownership interest	Consultant/advisory board	Other
Janice Y. Chyou	Icahn School of Medicine at Mount Sinai; Heart and Heart Rhythm Care	None	None	None	None	None	None	None
Rakesh Gopinathannair	Kansas City Heart Rhythm Institute	None	None	None	None	None	None	None
Ebrahim Barkoudah	Brigham and Women's Hospital	Bristol Myers Squibb (site PI)†; Janssen (2019, site PI)†; NIH/NHLBI (site PI)†	None	None	None	None	Janssen*; Novartis*; Pfizer*	Payments made to Brigham and Women's Hospital for performing clinical end points sponsored by various entities (end-point adjudicator)*
Jonathan W. Dukes	Community Memorial Hospital	None	Biosense Webster*; Boston Scientific*; Medtronic*	BMS*	State of California*	None	Biosense Webster†	None
Larry B. Goldstein	University of Kentucky	None	None	None	None	None	Janssen (DSMB; support to University of Kentucky)†	None
Jose A. Joglar	UT Southwestern Medical Center	None	None	None	None	None	None	None
Anson M. Lee	Stanford University	None	None	None	None	None	None	None
Steven A. Lubitz	Massachusetts General Hospital, Cardiovascular Research Center	NIH†; AHA†; BMS/Pfizer†; Boehringer Ingelheim†; IBM†; Fitbit†; Medtronic†; Premier, Inc†	None	None	None	None	Bristol-Myers Squibb†; Pfizer†; Blackstone Life Sciences*; Invitae*	Novartis (employee)†
Keith A. Marill	Massachusetts General Hospital	None	None	None	None	None	InCarda Therapeutics*	None
Kevin B. Sneed	University of South Florida Taneja College of Pharmacy	None	None	None	None	None	None	None
Megan M. Streur	University of Washington	NIH/NINR (K23NR017632 [PI])†	None	None	None	None	None	None
Graham C. Wong	University of British Columbia and Vancouver Coastal Health Authority (Canada)	None	None	Bayer Canada*	None	None	Novartis Canada*	None

This table represents the relationships of writing group members that may be perceived as actual or reasonably perceived conflicts of interest as reported on the Disclosure Questionnaire, which all members of the writing group are required to complete and submit. A relationship is considered to be "significant" if (a) the person receives \$5000 or more during any 12-month period, or 5% or more of the person's gross income; or (b) the person owns 5% or more of the voting stock or share of the entity or owns \$5000 or more of the fair market value of the entity. A relationship is considered to be "modest" if it is less than "significant" under the preceding definition.

\*Modest.

†Significant.

## Reviewer Disclosures

Reviewer	Employment	Research grant	Other research support	Speakers' bureau/honoraria	Expert witness	Ownership interest	Consultant/advisory board	Other
Amin Al-Ahmad	Texas Cardiac Arrhythmia	None	None	None	None	None	None	None
Thomas J. Bunch	University of Utah School of Medicine	Boehringer Ingelheim (research grant on the role of anticoagulation and risk of stroke and dementia in patients with atrial fibrillation)†; Boston Scientific (research grant on long-term impact of left atrial appendage closure on risk of stroke, dementia, and cognitive decline)†; Alta-thera (research grant on the economic impact of hospitalization for sotalol and dofetilide administration)†	None	None	None	None	None	None

(Continued)

Reviewer Disclosures Continued

Reviewer	Employment	Research grant	Other research support	Speakers' bureau/ honoraria	Expert witness	Ownership interest	Consultant/ advisory board	Other
Jason N. Katz	Duke University	None	None	None	None	None	None	None
Pamela J. McCabe	Mayo Clinic	None	None	None	None	None	None	None
Jonathan P. Piccini	Duke University Medical Center	AHA (grant to my institution for which I serve as PI)†; Abbott (grant to my institution for which I serve as PI)†; Gilead (grant to my institution for which I serve as PI)†; Johnson & Johnson (grant to my institution for which I serve as PI)†; NHLBI (grant to my institution for which I serve as PI)†; Philips (grant to my institution for which I serve as PI)†	None	None	None	None	Abbott†; Allergan*; Biontronik*; ARCA biopharma*; Boston Scientific†; JHJ*; LivaNova*; Philipst; Medtronic†; Sanofi†; Milestone*	None

This table represents the relationships of reviewers that may be perceived as actual or reasonably perceived conflicts of interest as reported on the Disclosure Questionnaire, which all reviewers are required to complete and submit. A relationship is considered to be “significant” if (a) the person receives \$5000 or more during any 12-month period, or 5% or more of the person’s gross income; or (b) the person owns 5% or more of the voting stock or share of the entity, or owns \$5000 or more of the fair market value of the entity. A relationship is considered to be “modest” if it is less than “significant” under the preceding definition.

\*Modest.  
†Significant.

REFERENCES

1. McIntyre WF, Um KJ, Cheung CC, Belley-Côté EP, Dingwall O, Devereaux PJ, Wong JA, Conen D, Whitlock RP, Connolly SJ, et al. Atrial fibrillation detected initially during acute medical illness: a systematic review. *Eur Heart J Acute Cardiovasc Care*. 2019;8:130–141. doi: 10.1177/2048872618799748

2. Bosch NA, Cimini J, Walkey AJ. Atrial fibrillation in the ICU. *Chest*. 2018;154:1424–1434. doi: 10.1016/j.chest.2018.03.040

3. Hyun J, Cho MS, Nam GB, Kim M, Do U, Kim J, Choi KJ, Kim YH. Natural course of new-onset postoperative atrial fibrillation after noncardiac surgery. *J Am Heart Assoc*. 2021;10:e018548. doi: 10.1161/JAHA.120.018548

4. Lubitz SA, Yin X, Rienstra M, Schnabel RB, Walkey AJ, Magnani JW, Rahman F, McManus DD, Tadros TM, Levy D, et al. Long-term outcomes of secondary atrial fibrillation in the community: the Framingham Heart Study. *Circulation*. 2015;131:1648–1655. doi: 10.1161/circulationaha.114.014058

5. McIntyre WF, Vadakkem ME, Rai AS, Thach T, Syed W, Um KJ, Ibrahim O, Dalmia S, Bhatnagar A, Mendoza PA, et al. Incidence and recurrence of new-onset atrial fibrillation detected during hospitalization for noncardiac surgery: a systematic review and meta-analysis. *Can J Anaesth*. 2021;68:1045–1056. doi: 10.1007/s12630-021-01944-0

6. Butt JH, Olesen JB, Havers-Borgersen E, Gundlund A, Andersson C, Gislason GH, Torp-Pedersen C, Kober L, Fosbol EL. Risk of thromboembolism associated with atrial fibrillation following noncardiac surgery. *J Am Coll Cardiol*. 2018;72:2027–2036. doi: 10.1016/j.jacc.2018.07.088

7. Wang EY, Hulme OL, Khurshid S, Weng LC, Choi SH, Walkey AJ, Ashburner JM, McManus DD, Singer DE, Atlas SJ, et al. Initial precipitants and recurrence of atrial fibrillation. *Circ Arrhythm Electrophysiol*. 2020;13:e007716. doi: 10.1161/CIRCEP.119.007716

8. Charitos EI, Herrmann FEM, Ziegler PD. Atrial fibrillation recurrence and spontaneous conversion to sinus rhythm after cardiac surgery: insights from 426 patients with continuous rhythm monitoring. *J Cardiovasc Electrophysiol*. 2021;32:2171–2178. doi: 10.1111/jce.15126

9. Abdelmoneim SS, Rosenberg E, Meykier M, Patel B, Reddy B, Ho J, Klem I, Singh J, Worku B, Tranbaugh RF, et al. The incidence and natural progression of new-onset postoperative atrial fibrillation. *JACC Clin Electrophysiol*. 2021;7:1134–1144. doi: 10.1016/j.jacep.2021.02.005

10. El-Chami MF, Merchant FM, Smith P, Levy M, Nelms AG, Merlino J, Puskas J, Leon AR. Management of new-onset postoperative atrial fibrillation utilizing insertable cardiac monitor technology to observe recurrence of AF (MONITOR-AF). *Pacing Clin Electrophysiol*. 2016;39:1083–1089. doi: 10.1111/pace.12949

11. Ahlsson A, Fengsrud E, Bodin L, Englund A. Postoperative atrial fibrillation in patients undergoing aortocoronary bypass surgery carries an eightfold risk of future atrial fibrillation and a doubled cardiovascular mortality. *Eur J Cardiothorac Surg*. 2010;37:1353–1359. doi: 10.1016/j.ejcts.2009.12.033

12. Melduni RM, Schaff HV, Bailey KR, Cha SS, Ammass NM, Seward JB, Gersh BJ. Implications of new-onset atrial fibrillation after cardiac surgery on long-term prognosis: a community-based study. *Am Heart J*. 2015;170:659–668. doi: 10.1016/j.ahj.2015.06.015

13. Funk M, Richards SB, Desjardins J, Bebon C, Wilcox H. Incidence, timing, symptoms, and risk factors for atrial fibrillation after cardiac surgery. *Am J Crit Care*. 2003;12:424–433. doi: 10.4037/ajcc2003.12.5.424

14. Lee SH, Kang DR, Uhm JS, Shim J, Sung JH, Kim JY, Pak HN, Lee MH, Joung B. New-onset atrial fibrillation predicts long-term newly developed atrial fibrillation after coronary artery bypass graft. *Am Heart J*. 2014;167:593–600.e1. doi: 10.1016/j.ahj.2013.12.010

15. Søgaard M, Skjøth F, Nielsen PB, Smit J, Dalager-Pedersen M, Larsen TB, Lip GYH. Thromboembolic risk in patients with pneumonia and new-onset atrial fibrillation not receiving anticoagulation therapy. *JAMA Netw Open*. 2022;5:e2213945. doi: 10.1001/jamanetworkopen.2022.13945

16. January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC Jr, Conti JB, Ellinor PT, Ezekowitz MD, Field ME, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society [published correction appears in *Circulation*. 2014;130:e272–e274]. *Circulation*. 2014;130:e199–e267. doi: 10.1161/CIR.0000000000000041

17. January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleveland JC Jr, Ellinor PT, Ezekowitz MD, Field ME, Furie KL, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society [published correction appears in *Circulation*. 2019;140:e285]. *Circulation*. 2019;140:e125–e151. doi: 10.1161/CIR.0000000000000665

18. Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, Boriani G, Castella M, Dan GA, Dilaveris PE, et al; ESC Scientific Document Group. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. *Eur Heart J*. 2021;42:373–498. doi: 10.1093/eurheartj/ehaa612

19. Calkins H, Hindricks G, Cappato R, Kim YH, Saad EB, Aguinaga L, Akar JG, Badhwar V, Brugada J, Camm J, et al. 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. *Heart Rhythm*. 2017;14:e275–e444. doi: 10.1016/j.hrthm.2017.05.012



20. Williams BA, Chamberlain AM, Blankenship JC, Hylek EM, Voyce S. Trends in atrial fibrillation incidence rates within an integrated health care delivery system, 2006 to 2018. *JAMA Netw Open*. 2020;3:e2014874. doi: 10.1001/jamanetworkopen.2020.14874
21. Walkey AJ, Wiener RS, Ghobrial JM, Curtis LH, Benjamin EJ. Incident stroke and mortality associated with new-onset atrial fibrillation in patients hospitalized with severe sepsis. *JAMA*. 2011;306:2248–2254. doi: 10.1001/jama.2011.1615
22. Massera D, Wang D, Vorchheimer DA, Negassa A, Garcia MJ. Increased risk of stroke and mortality following new-onset atrial fibrillation during hospitalization. *Europace*. 2017;19:929–936. doi: 10.1093/eurpace/euw110
23. Klein Klouwenberg PM, Frencken JF, Kuipers S, Ong DS, Peelen LM, van Vught LA, Schultz MJ, van der Poll T, Bonten MJ, Cremer OL. Incidence, predictors, and outcomes of new-onset atrial fibrillation in critically ill patients with sepsis: a cohort study. *Am J Respir Crit Care Med*. 2017;195:205–211. doi: 10.1164/rccm.201603-06180C
24. Kuipers S, Klein Klouwenberg PM, Cremer OL. Incidence, risk factors and outcomes of new-onset atrial fibrillation in patients with sepsis: a systematic review. *Crit Care*. 2014;18:688. doi: 10.1186/s13054-014-0688-5
25. Moss TJ, Calland JF, Enfield KB, Gomez-Manjarres DC, Ruminski C, DiMarco JP, Lake DE, Moorman JR. New-onset atrial fibrillation in the critically ill. *Crit Care Med*. 2017;45:790–797. doi: 10.1097/ccm.0000000000002325
26. Bedford J, Drikite L, Corbett M, Doidge J, Ferrando-Vivas P, Johnson A, Rajappan K, Mouncey P, Harrison D, Young D, et al. Pharmacological and non-pharmacological treatments and outcomes for new-onset atrial fibrillation in ICU patients: the CAFE scoping review and database analyses. *Health Technol Assess*. 2021;25:1–174. doi: 10.3310/hta25710
27. Chen AY, Sokol SS, Kress JP, Lat I. New-onset atrial fibrillation is an independent predictor of mortality in medical intensive care unit patients. *Ann Pharmacother*. 2015;49:523–527. doi: 10.1177/1060028015574726
28. Shaver CM, Chen W, Janz DR, May AK, Darbar D, Bernard GR, Bastarache JA, Ware LB. Atrial fibrillation is an independent predictor of mortality in critically ill patients. *Crit Care Med*. 2015;43:2104–2111. doi: 10.1097/ccm.0000000000001166
29. Bhavne PD, Goldman LE, Vittinghoff E, Maselli J, Auerbach A. Incidence, predictors, and outcomes associated with postoperative atrial fibrillation after major noncardiac surgery. *Am Heart J*. 2012;164:918–924. doi: 10.1016/j.ahj.2012.09.004
30. Siontis KC, Gersh BJ, Weston SA, Jiang R, Kashou AH, Roger VL, Noseworthy PA, Chamberlain AM. Association of new-onset atrial fibrillation after noncardiac surgery with subsequent stroke and transient ischemic attack. *JAMA*. 2020;324:871–878. doi: 10.1001/jama.2020.12518
31. Conen D, Alonso-Coello P, Douketis J, Chan MTV, Kurz A, Sigamani A, Parlow JL, Wang CY, Villar JC, Srinathan SK, et al. Risk of stroke and other adverse outcomes in patients with perioperative atrial fibrillation 1 year after non-cardiac surgery. *Eur Heart J*. 2020;41:645–651. doi: 10.1093/eurheartj/ehz431
32. Huynh JT, Healey JS, Um KJ, Vadakkan ME, Rai AS, Conen D, Meyre P, Butt JH, Kamel H, Reza SJ, et al. Association between perioperative atrial fibrillation and long-term risks of stroke and death in noncardiac surgery: systematic review and meta-analysis. *CJC Open*. 2021;3:666–674. doi: 10.1016/j.cjco.2020.12.025
33. Alturki A, Marafi M, Proietti R, Cardinale D, Blackwell R, Dorian P, Bessissow A, Vieira L, Greiss I, Essebag V, et al. Major adverse cardiovascular events associated with postoperative atrial fibrillation after noncardiac surgery: a systematic review and meta-analysis. *Circ Arrhythm Electrophysiol*. 2020;13:e007437. doi: 10.1161/CIRCEP.119.007437
34. Creswell LL, Schuessler RB, Rosenbloom M, Cox JL. Hazards of postoperative atrial arrhythmias. *Ann Thorac Surg*. 1993;56:539–549. doi: 10.1016/0003-4975(93)90894-n
35. Villareal RP, Hariharan R, Liu BC, Kar B, Lee VV, Elayda M, Lopez JA, Rasekh A, Wilson JM, Massumi A. Postoperative atrial fibrillation and mortality after coronary artery bypass surgery. *J Am Coll Cardiol*. 2004;43:742–748. doi: 10.1016/j.jacc.2003.11.023
36. Aranki SF, Shaw DP, Adams DH, Rizzo RJ, Couper GS, VanderVliet M, Collins JJ Jr, Cohn LH, Burstin HR. Predictors of atrial fibrillation after coronary artery surgery: current trends and impact on hospital resources. *Circulation*. 1996;94:390–397. doi: 10.1161/01.cir.94.3.390
37. Saxena A, Dinh DT, Smith JA, Shardey GC, Reid CM, Newcomb AE. Usefulness of postoperative atrial fibrillation as an independent predictor for worse early and late outcomes after isolated coronary artery bypass grafting (multicenter Australian study of 19,497 patients). *Am J Cardiol*. 2012;109:219–225. doi: 10.1016/j.amjcard.2011.08.033
38. Conen D, Wang MK, Devereaux PJ, Whitlock R, McIntyre WF, Healey JS, Yuan F, Yusuf S, Lamy A. New-onset perioperative atrial fibrillation after coronary artery bypass grafting and long-term risk of adverse events: an analysis from the CORONARY trial. *J Am Heart Assoc*. 2021;10:e020426. doi: 10.1161/JAHA.120.020426
39. Kosmidou I, Chen S, Kappetein AP, Serruys PW, Gersh BJ, Puskas JD, Kandzari DE, Taggart DP, Morice MC, Buszman PE, et al. New-onset atrial fibrillation after PCI or CABG for left main disease: the EXCEL trial. *J Am Coll Cardiol*. 2018;71:739–748. doi: 10.1016/j.jacc.2017.12.012
40. Taha A, Nielsen SJ, Bergfeldt L, Ahlsson A, Friberg L, Björck S, Franzén S, Jeppsson A. New-onset atrial fibrillation after coronary artery bypass grafting and long-term outcome: a population-based nationwide study from the SWEDEHEART registry. *J Am Heart Assoc*. 2021;10:e017966. doi: 10.1161/JAHA.120.017966
41. El-Chami MF, Kilgo P, Thourani V, Lattouf OM, Delurgio DB, Guyton RA, Leon AR, Puskas JD. New-onset atrial fibrillation predicts long-term mortality after coronary artery bypass graft. *J Am Coll Cardiol*. 2010;55:1370–1376. doi: 10.1016/j.jacc.2009.10.058
42. Gillinov AM, Bagiella E, Moskowitz AJ, Raiten JM, Groh MA, Bowdish ME, Ailawadi G, Kirkwood KA, Perrault LP, Parides MK, et al; CTSN. Rate control versus rhythm control for atrial fibrillation after cardiac surgery. *N Engl J Med*. 2016;374:1911–1921. doi: 10.1056/nejmoa1602002
43. Greenberg JW, Lancaster TS, Schuessler RB, Melby SJ. Postoperative atrial fibrillation following cardiac surgery: a persistent complication. *Eur J Cardiothorac Surg*. 2017;52:665–672. doi: 10.1093/ejcts/ezx039
44. Dobrev D, Aguilar M, Heijman J, Guichard JB, Nattel S. Postoperative atrial fibrillation: mechanisms, manifestations and management. *Nat Rev Cardiol*. 2019;16:417–436. doi: 10.1038/s41569-019-0166-5
45. Kotecha D, Castellá M. Is it time to treat post-operative atrial fibrillation just like regular atrial fibrillation? *Eur Heart J*. 2020;41:652–654a. doi: 10.1093/eurheartj/ehz412
46. Drossos G, Koutsogiannidis CP, Ananiadou O, Kapsas G, Ampatzidou F, Madesis A, Bismpa K, Palladas P, Karagounis L. Pericardial fat is strongly associated with atrial fibrillation after coronary artery bypass graft surgery. *Eur J Cardiothorac Surg*. 2014;46:1014–1020. doi: 10.1093/ejcts/ezu043
47. Haissaguerre M, Jais P, Shah DC, Takahashi A, Hocini M, Quiniou G, Garrigue S, Le Mouroux A, Le Métayer P, Clémenty J. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. *N Engl J Med*. 1998;339:659–666. doi: 10.1056/nejm199809033391003
48. Amar D, Zhang H, Miodownik S, Kadish AH. Competing autonomic mechanisms precede the onset of postoperative atrial fibrillation. *J Am Coll Cardiol*. 2003;42:1262–1268. doi: 10.1016/s0735-1097(03)00955-0
49. St-Onge S, Perrault LP, Demers P, Boyle EM, Gillinov AM, Cox J, Melby S. Pericardial blood as a trigger for postoperative atrial fibrillation after cardiac surgery. *Ann Thorac Surg*. 2018;105:321–328. doi: 10.1016/j.athoracsur.2017.07.045
50. Tisdale JE, Chung MK, Campbell KB, Hammadah M, Joglar JA, Leclerc J, Rajagopalan B; on behalf of the American Heart Association Clinical Pharmacology Committee of the Council on Clinical Cardiology and Council on Cardiovascular and Stroke Nursing. Drug-induced arrhythmias: a scientific statement from the American Heart Association. *Circulation*. 2020;142:e214–e233.
51. Lip GY, Nieuwlaar R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on Atrial Fibrillation. *Chest*. 2010;137:263–272. doi: 10.1378/chest.09.1584
52. Singer DE, Chang Y, Borowsky LH, Fang MC, Pomernacki NK, Udaltsova N, Reynolds K, Go AS. A new risk scheme to predict ischemic stroke and other thromboembolism in atrial fibrillation: the ATRIA study stroke risk score. *J Am Heart Assoc*. 2013;2:e000250. doi: 10.1161/JAHA.113.000250
53. De Vos CB, Pisters R, Nieuwlaar R, Prins MH, Tieleman RG, Coelen R-JS, van den Heijkant AC, Allesie MA, Crijns HJ. Progression from paroxysmal to persistent atrial fibrillation: clinical correlates and prognosis. *J Am Coll Cardiol*. 2010;55:725–731. doi: 10.1016/j.jacc.2009.11.040
54. Mariscalco G, Biancari F, Zanolini M, Cottini M, Piffaretti G, Saccocchi M, Banach M, Beghi C, Angelini GD. Bedside tool for predicting the risk of postoperative atrial fibrillation after cardiac surgery: the POAF score. *J Am Heart Assoc*. 2014;3:e000752. doi: 10.1161/JAHA.113.000752
55. Hsieh CY, Lee CH, Wu DP, Sung SF. Prediction of new-onset atrial fibrillation after first-ever ischemic stroke: a comparison of CHADS(2), CHA(2)DS(2)-VASc and HATCH scores and the added value of stroke severity. *Atherosclerosis*. 2018;272:73–79. doi: 10.1016/j.atherosclerosis.2018.03.024
56. Chua SK, Shyu KG, Lu MJ, Lien LM, Lin CH, Chao HH, Lo HM. Clinical utility of CHADS2 and CHA2DS2-VASc scoring systems for predicting postoperative atrial fibrillation after cardiac surgery. *J Thorac Cardiovasc Surg*. 2013;146:919–926.e1. doi: 10.1016/j.jtcvs.2013.03.040

57. Pieralli F, Biondo B, Vannucchi V, Falcone M, Antonielli E, De Marzi G, Casati C, Maddaluni L, Nozzoli C, Olivetto I. Performance of the CHA(2)DS(2)-VASc score in predicting new onset atrial fibrillation during hospitalization for community-acquired pneumonia. *Eur J Intern Med*. 2019;62:24–28. doi: 10.1016/j.ejim.2019.01.012
58. Burgos LM, Seoane L, Parodi JB, Espinoza J, Galizia Brito V, Benzadón M, Navia D. Postoperative atrial fibrillation is associated with higher scores on predictive indices. *J Thorac Cardiovasc Surg*. 2019;157:2279–2286. doi: 10.1016/j.jtcvs.2018.10.091
59. Kashani RG, Sareh S, Genovese B, Hershey C, Rezentes C, Shemin R, Buch E, Benharash P. Predicting postoperative atrial fibrillation using CHA2DS2-VASc scores. *J Surg Res*. 2015;198:267–272. doi: 10.1016/j.jss.2015.04.047
60. Selvi M, Gungor H, Zencir C, Gulasti S, Eryilmaz U, Akgullu C, Durmaz S. A new predictor of atrial fibrillation after coronary artery bypass graft surgery: HATCH score. *J Invest Med*. 2018;66:648–652. doi: 10.1136/jim-2017-000525
61. Uysal D, Aksoy F, Ibrşim E. The validation of the ATRIA and CHA2DS2-Vasc scores in predicting atrial fibrillation after coronary artery bypass surgery. *Braz J Cardiovasc Surg*. 2020;35:619–625.
62. Luo J, Dai L, Li J, Zhao J, Li Z, Qin X, Li H, Liu B, Wei Y. Risk evaluation of new-onset atrial fibrillation complicating ST-segment elevation myocardial infarction: a comparison between GRACE and CHA(2)DS(2)-VASc scores. *Clin Interv Aging*. 2018;13:1099–1109. doi: 10.2147/CIA.S166100
63. Chen YL, Zeng M, Liu Y, Xu Y, Bai Y, Cao L, Ling Z, Fan J, Yin Y. CHA(2)DS(2)-VASc score for identifying patients at high risk of postoperative atrial fibrillation after cardiac surgery: a meta-analysis. *Ann Thorac Surg*. 2020;109:1210–1216. doi: 10.1016/j.athoracsurg.2019.07.084
64. Wazni OM, Martin DO, Marrouche NF, Latif AA, Ziada K, Shaaraoui M, Almahameed S, Schweikert RA, Saliba WJ, Gillinov AM, et al. Plasma B-type natriuretic peptide levels predict postoperative atrial fibrillation in patients undergoing cardiac surgery. *Circulation*. 2004;110:124–127. doi: 10.1161/01.CIR.0000134481.24511.BC
65. Shibazaki K, Kimura K, Fujii S, Sakai K, Iguchi Y. Brain natriuretic peptide levels as a predictor for new atrial fibrillation during hospitalization in patients with acute ischemic stroke. *Am J Cardiol*. 2012;109:1303–1307. doi: 10.1016/j.amjcard.2011.12.022
66. Muehlschlegel JD, Burrage PS, Ngai JY, Prutkin JM, Huang CC, Xu X, Chae SH, Bollen BA, Piccini JP, Schwann NM, et al. Society of Cardiovascular Anesthesiologists/European Association of Cardiothoracic Anaesthetists practice advisory for the management of perioperative atrial fibrillation in patients undergoing cardiac surgery. *Anesth Analg*. 2019;128:33–42. doi: 10.1213/ane.0000000000003865
67. Burgos LM, Ramírez AG, Seoane L, Furmento JF, Costabel JP, Diez M, Navia D. New combined risk score to predict atrial fibrillation after cardiac surgery: COM-AF. *Ann Card Anaesth*. 2021;24:458–463. doi: 10.4103/aca.ACA\_34\_20
68. Pluymaekers NA, Hermans AN, Linz DK, Dudink EA, Luermans JG, Weijts B, Vernooy K, Crijns HJ. Frequency and determinants of spontaneous conversion to sinus rhythm in patients presenting to the emergency department with recent-onset atrial fibrillation: a systematic review. *Arrhythm Electrophysiol Rev*. 2020;9:195–201. doi: 10.15420/aer.2020.34
69. Lip GY, Watson T. Atrial fibrillation (acute onset). *BMJ Clin Evid*. 2008;2008:0210.
70. Pluymaekers N, Dudink E, Luermans J, Meeder JG, Lenderink T, Widdershoven J, Buxx JJJ, Rienstra M, Kamp O, Van Opstal JM, et al. Early or delayed cardioversion in recent-onset atrial fibrillation. *N Engl J Med*. 2019;380:1499–1508. doi: 10.1056/NEJMoa1900353
71. Geleris P, Stavratou A, Afthonidis D, Kirpizidis H, Boudoulas H. Spontaneous conversion to sinus rhythm of recent (within 24 hours) atrial fibrillation. *J Cardiol*. 2001;37:103–107.
72. Danias PG, Caulfield TA, Weigner MJ, Silverman DI, Manning WJ. Likelihood of spontaneous conversion of atrial fibrillation to sinus rhythm. *J Am Coll Cardiol*. 1998;31:588–592. doi: 10.1016/s0735-1097(97)00534-2
73. Skinner NS Jr, Mitchell JH, Wallace AG, Sarnoff SJ. Hemodynamic consequences of atrial fibrillation at constant ventricular rates. *Am J Med*. 1964;36:342–350. doi: 10.1016/0002-9343(64)90160-3
74. Naito M, David D, Michelson EL, Schaffenburg M, Dreifus LS. The hemodynamic consequences of cardiac arrhythmias: evaluation of the relative roles of abnormal atrioventricular sequencing, irregularity of ventricular rhythm and atrial fibrillation in a canine model. *Am Heart J*. 1983;106:284–291. doi: 10.1016/0002-8703(83)90194-1
75. Scheuermeyer FX, Pourvali R, Rowe H, Grafstein E, Heslop C, MacPhee J, McGrath L, Ward J, Heilbron B, Christenson J. Emergency department patients with atrial fibrillation or flutter and an acute underlying medical illness may not benefit from attempts to control rate or rhythm. *Ann Emerg Med*. 2015;65:511–522.e2. doi: 10.1016/j.annemergmed.2014.09.012
76. Darby AE, Dimarco JP. Management of atrial fibrillation in patients with structural heart disease. *Circulation*. 2012;125:945–957. doi: 10.1161/circulationaha.111.019935
77. Heist EK, Mansour M, Ruskin JN. Rate control in atrial fibrillation: targets, methods, resynchronization considerations. *Circulation*. 2011;124:2746–2755. doi: 10.1161/circulationaha.111.019919
78. Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB, Kellen JC, Greene HL, Mickel MC, Dalquist JE, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. *N Engl J Med*. 2002;347:1825–1833. doi: 10.1056/NEJMoa021328
79. Stratton T, Nasser L. BET 1: lenient or strict rate control for atrial fibrillation. *Emerg Med J*. 2018;35:765–768. doi: 10.1136/emered-2018-208261.1
80. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M, Diener HC, Heidbuchel H, Hendriks J, et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. *Eur Heart J*. 2016;37:2893–2962. doi: 10.1093/eurheartj/ehw210
81. Andrade JG, Aguilar M, Atzema C, Bell A, Cairns JA, Cheung CC, Cox JL, Dorian P, Gladstone DJ, Healey JS, et al. The 2020 Canadian Cardiovascular Society/Canadian Heart Rhythm Society comprehensive guidelines for the management of atrial fibrillation. *Can J Cardiol*. 2020;36:1847–1948. doi: 10.1016/j.cjca.2020.09.001
82. Panchal AR, Bartos JA, Cabañas JG, Donnino MW, Drennan IR, Hirsch KG, Kudenchuk PJ, Kurz MC, Lavonas EJ, Morley PT, et al; on behalf of the Adult Basic and Advanced Life Support Writing Group. Part 3: adult basic and advanced life support: 2020 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. *Circulation*. 2020;142:S366–s468. doi: 10.1161/CIR.0000000000000916
83. Hernández-Madrid A, Svendsen JH, Lip GY, Van Gelder IC, Dobreaanu D, Blomstrom-Lundqvist C. Cardioversion for atrial fibrillation in current European practice: results of the European Heart Rhythm Association survey. *Europace*. 2013;15:915–918. doi: 10.1093/europace/eut143
84. Stiell IG, Macle L; CCS Atrial Fibrillation Guidelines Committee. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: management of recent-onset atrial fibrillation and flutter in the emergency department. *Can J Cardiol*. 2011;27:38–46. doi: 10.1016/j.cjca.2010.11.014
85. Crijns HJ, Weijts B, Fairley AM, Lewalter T, Maggioni AP, Martín A, Ponikowski P, Rosenqvist M, Sanders P, Scanavacca M, et al. Contemporary real life cardioversion of atrial fibrillation: results from the multinational RHYTHM-AF study. *Int J Cardiol*. 2014;172:588–594. doi: 10.1016/j.ijcard.2014.01.099
86. Pisters R, Nieuwlaar R, Prins MH, Le Heuzey JY, Maggioni AP, Camm AJ, Crijns HJ. Clinical correlates of immediate success and outcome at 1-year follow-up of real-world cardioversion of atrial fibrillation: the Euro Heart Survey. *Europace*. 2012;14:666–674. doi: 10.1093/europace/eur406
87. Stiell IG, Sivilotti MLA, Taljaard M, Birnie D, Vadeboncoeur A, Hohl CM, McRae AD, Rowe BH, Brison RJ, Thiruganasambandamoorthy V, et al. Electrical versus pharmacological cardioversion for emergency department patients with acute atrial fibrillation (RAFF2): a partial factorial randomised trial. *Lancet*. 2020;395:339–349. doi: 10.1016/S0140-6736(19)32994-0
88. Ellenbogen KA, Clemo HF, Stamler BS, Wood MA, Vanderlugt JT. Efficacy of ibutilide for termination of atrial fibrillation and flutter. *Am J Cardiol*. 1996;78:42–45. doi: 10.1016/s0002-9149(96)00565-6
89. Vanderlugt JT, Mattioni T, Denker S, Torchiana D, Ahern T, Wakefield LK, Perry KT, Kowey PR. Efficacy and safety of ibutilide fumarate for the conversion of atrial arrhythmias after cardiac surgery. *Circulation*. 1999;100:369–375. doi: 10.1161/01.cir.100.4.369
90. Pedersen OD, Bagger H, Keller N, Marchant B, Køber L, Torp-Pedersen C. Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function: a Danish Investigations of Arrhythmia and Mortality on Dofetilide (DIAMOND) substudy. *Circulation*. 2001;104:292–296. doi: 10.1161/01.cir.104.3.292
91. Alboni P, Botto GL, Baldi N, Luzzi M, Russo V, Gianfranchi L, Marchi P, Calzolari M, Solano A, Baroffio R, et al. Outpatient treatment of recent-onset atrial fibrillation with the “pill-in-the-pocket” approach. *N Engl J Med*. 2004;351:2384–2391. doi: 10.1056/nejmoa041233
92. Khan IA. Single oral loading dose of propafenone for pharmacological cardioversion of recent-onset atrial fibrillation. *J Am Coll Cardiol*. 2001;37:542–547. doi: 10.1016/s0735-1097(00)01116-5
93. Singh BN, Singh SN, Reda DJ, Tang XC, Lopez B, Harris CL, Fletcher RD, Sharma SC, Atwood JE, Jacobson AK, et al. Amiodarone versus sotalol for atrial fibrillation. *N Engl J Med*. 2005;352:1861–1872. doi: 10.1056/NEJMoa041705

94. Kowey PR, Dorian P, Mitchell LB, Pratt CM, Roy D, Schwartz PJ, Sadowski J, Sobczyk D, Bochenek A, Toft E. Vernakalant hydrochloride for the rapid conversion of atrial fibrillation after cardiac surgery: a randomized, double-blind, placebo-controlled trial. *Circ Arrhythm Electrophysiol*. 2009;2:652–659. doi: 10.1161/CIRCEP.109.870204
95. Arrigo M, Jaeger N, Seifert B, Spahn DR, Bettex D, Rudiger A. Disappointing success of electrical cardioversion for new-onset atrial fibrillation in cardiothoracic ICU patients. *Crit Care Med*. 2015;43:2354–2359. doi: 10.1097/ccm.0000000000001257
96. Burton JH, Vinson DR, Drummond K, Strout TD, Thode HC, McInturf JJ. Electrical cardioversion of emergency department patients with atrial fibrillation. *Ann Emerg Med*. 2004;44:20–30. doi: 10.1016/j.annemergmed.2004.02.016
97. Cristoni L, Tampieri A, Mucci F, Iannone P, Venturi A, Cavazza M, Lenzi T. Cardioversion of acute atrial fibrillation in the short observation unit: comparison of a protocol focused on electrical cardioversion with simple antiarrhythmic treatment. *Emerg Med J*. 2011;28:932–937. doi: 10.1136/emj.2009.083196
98. Dankner R, Shahar A, Novikov I, Agmon U, Ziv A, Hod H. Treatment of stable atrial fibrillation in the emergency department: a population-based comparison of electrical direct-current versus pharmacological cardioversion or conservative management. *Cardiology*. 2009;112:270–278. doi: 10.1159/000151703
99. Jacoby JL, Cesta M, Heller MB, Salen P, Reed J. Synchronized emergency department cardioversion of atrial dysrhythmias saves time, money and resources. *J Emerg Med*. 2005;28:27–30. doi: 10.1016/j.jemermed.2004.07.011
100. Lo GK, Fatovich DM, Haig AD. Biphasic cardioversion of acute atrial fibrillation in the emergency department. *Emerg Med J*. 2006;23:51–53. doi: 10.1136/emj.2004.021055
101. Stiell IG, Clement CM, Brison RJ, Rowe BH, Borgundvaag B, Langhan T, Lang E, Magee K, Stenstrom R, Perry JJ, et al. Variation in management of recent-onset atrial fibrillation and flutter among academic hospital emergency departments. *Ann Emerg Med*. 2011;57:13–21. doi: 10.1016/j.annemergmed.2010.07.005
102. Brandes A, Crijns H, Rienstra M, Kirchhof P, Grove EL, Pedersen KB, Van Gelder IC. Cardioversion of atrial fibrillation and atrial flutter revisited: current evidence and practical guidance for a common procedure. *Europace*. 2020;22:1149–1161. doi: 10.1093/europace/eaab057
103. Mittal S, Ayati S, Stein KM, Schwartzman D, Cavlovich D, Tchou PJ, Markowitz SM, Slotwiner DJ, Scheiner MA, Lerman BB. Transthoracic cardioversion of atrial fibrillation: comparison of rectilinear biphasic versus damped sine wave monophasic shocks. *Circulation*. 2000;101:1282–1287. doi: 10.1161/01.cir.101.11.1282
104. Schmidt AS, Lauridsen KG, Torp P, Bach LF, Rieckers H, Løfgren B. Maximum-fixed energy shocks for cardioverting atrial fibrillation. *Eur Heart J*. 2020;41:626–631. doi: 10.1093/eurheartj/ehz585
105. Kirchhof P, Eckardt L, Loh P, Weber K, Fischer RJ, Seidl KH, Böcker D, Breithardt G, Haverkamp W, Borggreve M. Anterior-posterior versus anterior-lateral electrode positions for external cardioversion of atrial fibrillation: a randomised trial. *Lancet*. 2002;360:1275–1279. doi: 10.1016/s0140-6736(02)11315-8
106. Um KJ, McIntyre WF, Healey JS, Mendoza PA, Koziarz A, Amit G, Chu VA, Whitlock RP, Belley-Côté EP. Pre- and post-treatment with amiodarone for elective electrical cardioversion of atrial fibrillation: a systematic review and meta-analysis. *Europace*. 2019;21:856–863. doi: 10.1093/europace/euy310
107. Voskoboinik A, Moskvitch J, Plunkett G, Bloom J, Wong G, Nalliah C, Prabhu S, Sugumar H, Paramaswaran R, McLellan A, et al. Cardioversion of atrial fibrillation in obese patients: results from the Cardioversion-BMI randomized controlled trial. *J Cardiovasc Electrophysiol*. 2019;30:155–161. doi: 10.1111/jce.13786
108. Hocini M, Sanders P, Deisenhofer I, Jaïs P, Hsu LF, Scavée C, Weerasoriya R, Raybaud F, Macle L, Shah DC, et al. Reverse remodeling of sinus node function after catheter ablation of atrial fibrillation in patients with prolonged sinus pauses. *Circulation*. 2003;108:1172–1175. doi: 10.1161/01.CIR.0000090685.13169.07
109. Gibson CM, Spyropoulos AC, Cohen AT, Hull RD, Goldhaber SZ, Yusen RD, Hernandez AF, Korjian S, Daaboul Y, Gold A, et al. The IMPROVED VTE risk score: incorporation of D-dimer into the IMPROVE score to improve venous thromboembolism risk stratification. *TH Open*. 2017;1:e56–e65. doi: 10.1055/s-0037-1603929
110. Cohen A, Ederhy S, Meuleman C, Di Angelantonio E, Dufaitre G, Boccara F. D-dimers in atrial fibrillation: a further step in risk stratification of thrombo-embolism? *Eur Heart J*. 2007;28:2179–2180. doi: 10.1093/eurheartj/ehm170
111. Salabei JK, Fishman TJ, Aslake ZT, Ali A, Iyer UG. COVID-19 coagulopathy: current knowledge and guidelines on anticoagulation. *Heart Lung*. 2021;50:357–360. doi: 10.1016/j.hrtlung.2021.01.011
112. Semeraro N, Ammolio CT, Semeraro F, Colucci M. Coagulopathy of acute sepsis. *Semin Thromb Hemost*. 2015;41:650–658. doi: 10.1055/s-0035-1556730
113. Undas A. Altered fibrin clot properties and fibrinolysis in patients with atrial fibrillation: practical implications. *Europace*. 2020;22:185–194. doi: 10.1093/europace/euz271
114. Go AS, Reynolds K, Yang J, Gupta N, Lenane J, Sung SH, Harrison TN, Liu TI, Solomon MD. Association of burden of atrial fibrillation with risk of ischemic stroke in adults with paroxysmal atrial fibrillation: the KP-RHYTHM study. *JAMA Cardiol*. 2018;3:601–608. doi: 10.1001/jamacardio.2018.1176
115. Chen LY, Chung MK, Allen LA, Ezekowitz M, Furie KL, McCabe P, Noseworthy PA, Perez MV, Turakhia MP, on behalf of the American Heart Association Council on Clinical Cardiology; Council on Cardiovascular and Stroke Nursing; Council on Quality of Care and Outcomes Research; and Stroke Council. Atrial fibrillation burden: moving beyond atrial fibrillation as a binary entity: a scientific statement from the American Heart Association. *Circulation*. 2018;137:e623–e644. doi: 10.1161/CIR.0000000000000568
116. Fatkin D, Kuchar DL, Thorburn CW, Feneley MP. Transesophageal echocardiography before and during direct current cardioversion of atrial fibrillation: evidence for “atrial stunning” as a mechanism of thromboembolic complications. *J Am Coll Cardiol*. 1994;23:307–316. doi: 10.1016/0735-1097(94)90412-x
117. Lip GY. Cardioversion of atrial fibrillation. *Postgrad Med J*. 1995;71:457–465. doi: 10.1136/pgmj.71.838.457
118. Lip GY, Gitt AK, Le Heuzey JY, Bash LD, Morabito CJ, Bernhardt AA, Sisk CM, Chazelle F, Crijns HJ. Overtreatment and undertreatment with anticoagulation in relation to cardioversion of atrial fibrillation (the RHYTHM-AF study). *Am J Cardiol*. 2014;113:480–484. doi: 10.1016/j.amjcard.2013.10.036
119. Airaksinen KE, Grönberg T, Nuotio I, Nikkinen M, Ylitalo A, Biancari F, Hartikainen JE. Thromboembolic complications after cardioversion of acute atrial fibrillation: the FinCV (Finnish CardioVersion) study. *J Am Coll Cardiol*. 2013;62:1187–1192. doi: 10.1016/j.jacc.2013.04.089
120. Nuotio I, Hartikainen JE, Grönberg T, Biancari F, Airaksinen KE. Time to cardioversion for acute atrial fibrillation and thromboembolic complications. *JAMA*. 2014;312:647–649. doi: 10.1001/jama.2014.3824
121. Grönberg T, Hartikainen JE, Nuotio I, Biancari F, Ylitalo A, Airaksinen KE. Anticoagulation, CHA2DS2-VASc score, and thromboembolic risk of cardioversion of acute atrial fibrillation (from the FinCV Study). *Am J Cardiol*. 2016;117:1294–1298. doi: 10.1016/j.amjcard.2016.01.024
122. Sjalander S, Svensson PJ, Friberg L. Atrial fibrillation patients with CHA2DS2-VASc >1 benefit from oral anticoagulation prior to cardioversion. *Int J Cardiol*. 2016;215:360–363. doi: 10.1016/j.ijcard.2016.04.031
123. Wong BM, Perry JJ, Cheng W, Zheng B, Guo K, Taljaard M, Skanes AC, Stiell IG. Thromboembolic events following cardioversion of acute atrial fibrillation and flutter: a systematic review and meta-analysis. *CJEM*. 2021;23:500–511. doi: 10.1007/s43678-021-00103-0
124. Spagnolo P, Giglio M, Di Marco D, Cannà PM, Agricola E, Della Bella PE, Monti CB, Sardanelli F. Diagnosis of left atrial appendage thrombus in patients with atrial fibrillation: delayed contrast-enhanced cardiac CT. *Eur Radiol*. 2021;31:1236–1244. doi: 10.1007/s00330-020-07172-2
125. Romero J, Husain SA, Kelesidis I, Sanz J, Medina HM, Garcia MJ. Detection of left atrial appendage thrombus by cardiac computed tomography in patients with atrial fibrillation: a meta-analysis. *Circ Cardiovasc Imaging*. 2013;6:185–194. doi: 10.1161/CIRCIMAGING.112.000153
126. Pathan F, Hecht H, Narula J, Marwick TH. Roles of transesophageal echocardiography and cardiac computed tomography for evaluation of left atrial thrombus and associated pathology: a review and critical analysis. *JACC Cardiovasc Imaging*. 2018;11:616–627. doi: 10.1016/j.jcmg.2017.12.019
127. Stellbrink C, Nixdorff U, Hofmann T, Lehmann W, Daniel WG, Hanrath P, Geller C, Mügge A, Sehnert W, Schmidt-Lucke C, et al. Safety and efficacy of enoxaparin compared with unfractionated heparin and oral anticoagulants for prevention of thromboembolic complications in cardioversion of nonvalvular atrial fibrillation: the Anticoagulation in Cardioversion using Enoxaparin (ACE) trial. *Circulation*. 2004;109:997–1003. doi: 10.1161/01.CIR.0000120509.64740.DC
128. Klein AL, Grimm RA, Murray RD, Apperson-Hansen C, Asinger RW, Black IW, Davidoff R, Erbel R, Halperin JL, Orsinelli DA, et al. Use



- of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. *N Engl J Med*. 2001;344:1411–1420. doi: 10.1056/NEJM200105103441901
129. Cappato R, Ezekowitz MD, Klein AL, Camm AJ, Ma CS, Le Heuzey JY, Talajic M, Scanavacca M, Vardas PE, Kirchhof P, et al. Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation. *Eur Heart J*. 2014;35:3346–3355. doi: 10.1093/eurheartj/ehu367
  130. Goette A, Merino JL, Ezekowitz MD, Zamoryakhin D, Melino M, Jin J, Mercuri MF, Grosso MA, Fernandez V, Al-Saady N, et al. Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial. *Lancet*. 2016;388:1995–2003. doi: 10.1016/S0140-6736(16)31474-X
  131. Nagarakanti R, Ezekowitz MD, Oldgren J, Yang S, Chernick M, Aikens TH, Flaker G, Brugada J, Kamensky G, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. *Circulation*. 2011;123:131–136. doi: 10.1161/circulationaha.110.977546
  132. Piccini JP, Stevens SR, Lokhnygina Y, Patel MR, Halperin JL, Singer DE, Hankey GJ, Hacke W, Becker RC, Nessel CC, et al. Outcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial. *J Am Coll Cardiol*. 2013;61:1998–2006. doi: 10.1016/j.jacc.2013.02.025
  133. Flaker G, Lopes RD, Al-Khatib SM, Hermosillo AG, Hohnloser SH, Tinga B, Zhu J, Mohan P, Garcia D, Bartunek J, et al. Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation). *J Am Coll Cardiol*. 2014;63:1082–1087. doi: 10.1016/j.jacc.2013.09.062
  134. Plitt A, Ezekowitz MD, De Caterina R, Nordio F, Peterson N, Giugliano RP. Cardioversion of atrial fibrillation in ENGAGE AF-TIMI 48. *Clin Cardiol*. 2016;39:345–346. doi: 10.1002/clc.22537
  135. Ezekowitz MD, Pollack CV Jr, Halperin JL, England RD, VanPelt Nguyen S, Spahr J, Sudworth M, Cater NB, Breazna A, Oldgren J, et al. Apixaban compared to heparin/vitamin K antagonist in patients with atrial fibrillation scheduled for cardioversion: the EMANATE trial. *Eur Heart J*. 2018;39:2959–2971. doi: 10.1093/eurheartj/ehy148
  136. Kotecha D, Pollack CV Jr, De Caterina R, Renda G, Kirchhof P. Direct oral anticoagulants halve thromboembolic events after cardioversion of AF compared with warfarin. *J Am Coll Cardiol*. 2018;72:1984–1986. doi: 10.1016/j.jacc.2018.07.083
  137. Bellew SD, Bremer ML, Kopecky SL, Lohse CM, Munger TM, Robelia PM, Smars PA. Impact of an emergency department observation unit management algorithm for atrial fibrillation. *J Am Heart Assoc*. 2016;5:e002984. doi: 10.1161/JAHA.115.002984
  138. Coll-Vinent B, Martin A, Sanchez J, Tamargo J, Suero C, Malagon F, Varona M, Cancio M, Sanchez S, Carbajosa J, et al; EMERG-AF Investigators. Benefits of emergency departments' contribution to stroke prophylaxis in atrial fibrillation: the EMERG-AF Study (Emergency Department Stroke Prophylaxis and Guidelines Implementation in Atrial Fibrillation). *Stroke*. 2017;48:1344–1352. doi: 10.1161/strokeaha.116.014855
  139. Stiell IG, de Wit K, Scheuermeyer FX, Vadeboncoeur A, Angaran P, Eagles D, Graham ID, Atzema CL, Archambault PM, Tebbenham T, et al. 2021 CAEP acute atrial fibrillation/flutter best practices checklist. *CJEM*. 2021;23:604–610. doi: 10.1007/s43678-021-00167-y
  140. Balik M, Kolnikova I, Maly M, Waldauf P, Tavazzi G, Kristof J. Propafenone for supraventricular arrhythmias in septic shock: comparison to amiodarone and metoprolol. *J Crit Care*. 2017;41:16–23. doi: 10.1016/j.jccr.2017.04.027
  141. Moskowitz A, Chen KP, Cooper AZ, Chahin A, Ghassemi MM, Celi LA. Management of atrial fibrillation with rapid ventricular response in the intensive care unit: a secondary analysis of electronic health record data. *Shock*. 2017;48:436–440. doi: 10.1097/shk.0000000000000869
  142. Morelli A, Singer M, Ranieri VM, D'Egidio A, Mascia L, Orecchioni A, Piscioneri F, Guarracino F, Greco E, Peruzzi M, et al. Heart rate reduction with esmolol is associated with improved arterial elastance in patients with septic shock: a prospective observational study. *Intensive Care Med*. 2016;42:1528–1534. doi: 10.1007/s00134-016-4351-2
  143. Morelli A, Ertmer C, Westphal M, Rehberg S, Kampmeier T, Ligges S, Orecchioni A, D'Egidio A, D'Ipolti F, Raffone C, et al. Effect of heart rate control with esmolol on hemodynamic and clinical outcomes in patients with septic shock: a randomized clinical trial. *JAMA*. 2013;310:1683–1691. doi: 10.1001/jama.2013.278477
  144. Walkey AJ, Evans SR, Winter MR, Benjamin EJ. Practice patterns and outcomes of treatments for atrial fibrillation during sepsis: a propensity-matched cohort study. *Chest*. 2016;149:74–83. doi: 10.1378/chest.15-0959
  145. Bedford JP, Johnson A, Redfern O, Gerry S, Doidge J, Harrison D, Rajappan K, Rowan K, Young JD, Mouncey P, et al. Comparative effectiveness of common treatments for new-onset atrial fibrillation within the ICU: accounting for physiological status. *J Crit Care*. 2022;67:149–156. doi: 10.1016/j.jccr.2021.11.005
  146. Walkey AJ, Quinn EK, Winter MR, McManus DD, Benjamin EJ. Practice patterns and outcomes associated with use of anticoagulation among patients with atrial fibrillation during sepsis. *JAMA Cardiol*. 2016;1:682–690. doi: 10.1001/jamacardio.2016.2181
  147. Quon MJ, Behloul H, Pilote L. Anticoagulant use and risk of ischemic stroke and bleeding in patients with secondary atrial fibrillation associated with acute coronary syndromes, acute pulmonary disease, or sepsis. *JACC Clin Electrophysiol*. 2018;4:386–393. doi: 10.1016/j.jacep.2017.08.003
  148. Levi M, Schultz M, van der Poll T. Sepsis and thrombosis. *Semin Thromb Hemost*. 2013;39:559–566. doi: 10.1055/s-0033-1343894
  149. Musikantow DR, Turagam MK, Sartori S, Chu E, Kawamura I, Shivamurthy P, Bokhari M, Oates C, Zhang C, Pumill C, et al. Atrial fibrillation in patients hospitalized with COVID-19: incidence, predictors, outcomes, and comparison to influenza. *JACC Clin Electrophysiol*. 2021;7:1120–1130. doi: 10.1016/j.jacep.2021.02.009
  150. Bhatla A, Mayer MM, Adusumalli S, Hyman MC, Oh E, Tierney A, Moss J, Chahal AA, Anesi G, Denduluri S, et al. COVID-19 and cardiac arrhythmias. *Heart Rhythm*. 2020;17:1439–1444. doi: 10.1016/j.hrthm.2020.06.016
  151. McBane RD 2nd, Torres Roldan VD, Niven AS, Pruthi RK, Franco PM, Linderbaum JA, Casanegra AI, Oyen LJ, Houghton DE, Marshall AL, et al. Anticoagulation in COVID-19: a systematic review, meta-analysis, and rapid guidance from Mayo Clinic. *Mayo Clin Proc*. 2020;95:2467–2486. doi: 10.1016/j.mayocp.2020.08.030
  152. Ageno W, De Candia E, Iacoviello L, Di Castelnuovo A. Protective effect of oral anticoagulant drugs in atrial fibrillation patients admitted for COVID-19: results from the CORIST study. *Thromb Res*. 2021;203:138–141. doi: 10.1016/j.thromres.2021.05.006
  153. Lopes RD, de Barros ESPGM, Furtado RHM, Macedo AVS, Bronhara B, Damiani LP, Barbosa LM, de Aveiro Morata J, Ramacciotti E, de Aquino Martins P, et al. Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial. *Lancet*. 2021;397:2253–2263. doi: 10.1016/S0140-6736(21)01203-4
  154. Lawler PR, Goligher EC, Berger JS, Neal MD, McVerry BJ, Nicolau JC, Gong MN, Carrier M, Rosenson RS, Reynolds HR, et al. Therapeutic anticoagulation with heparin in noncritically ill patients with Covid-19. *N Engl J Med*. 2021;385:790–802. doi: 10.1056/NEJMoa2105911
  155. Goligher EC, Bradbury CA, McVerry BJ, Lawler PR, Berger JS, Gong MN, Carrier M, Reynolds HR, Kumar A, Turgeon AF, et al. Therapeutic anticoagulation with heparin in critically ill patients with Covid-19. *N Engl J Med*. 2021;385:777–789. doi: 10.1056/NEJMoa2103417
  156. Ramacciotti E, Barile Agati L, Calderaro D, Aguiar VCR, Spyropoulos AC, de Oliveira CCC, Lins Dos Santos J, Volpiani G, Sobreira ML, Joviliano EE, et al. Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial. *Lancet*. 2022;399:50–59. doi: 10.1016/S0140-6736(21)02392-8
  157. Stuijver DJ, van Zaane B, Romualdi E, Brandjes DP, Gerdes VE, Squizzato A. The effect of hyperthyroidism on procoagulant, anticoagulant and fibrinolytic factors: a systematic review and meta-analysis. *Thromb Haemost*. 2012;108:1077–1088. doi: 10.1160/TH12-07-0496
  158. Kim K, Yang PS, Jang E, Yu HT, Kim TH, Uhm JS, Kim JY, Sung JH, Pak HN, Lee MH, et al. Increased risk of ischemic stroke and systemic embolism in hyperthyroidism-related atrial fibrillation: a nationwide cohort study. *Am Heart J*. 2021;242:123–131. doi: 10.1016/j.ahj.2021.08.018
  159. Singer DE, Ziegler PD, Koehler JL, Sarkar S, Passman RS. Temporal association between episodes of atrial fibrillation and risk of ischemic stroke. *JAMA Cardiol*. 2021;6:1364–1369. doi: 10.1001/jamacardio.2021.3702
  160. Glotzer TV, Daoud EG, Wyse DG, Singer DE, Ezekowitz MD, Hilker C, Miller C, Qi D, Ziegler PD. The relationship between daily atrial tachyarrhythmia burden from implantable device diagnostics and stroke risk: the TRENDS study. *Circ Arrhythm Electrophysiol*. 2009;2:474–480. doi: 10.1161/CIRCEP.109.849638
  161. Camen S, Ojeda FM, Niiranen T, Gianfagna F, Vishram-Nielsen JK, Costanzo S, Söderberg S, Vartiainen E, Donati MB, Løchen ML, et al. Temporal relations between atrial fibrillation and ischaemic stroke and their prognostic impact on mortality. *Europace*. 2020;22:522–529. doi: 10.1093/europace/euz312



162. Brambatti M, Connolly SJ, Gold MR, Morillo CA, Capucci A, Muto C, Lau CP, Van Gelder IC, Hohnloser SH, Carlson M, et al. Temporal relationship between subclinical atrial fibrillation and embolic events. *Circulation*. 2014;129:2094–2099. doi: 10.1161/circulationaha.113.007825
163. Daoud EG, Glotzer TV, Wyse DG, Ezekowitz MD, Hilker C, Koehler J, Ziegler PD. Temporal relationship of atrial tachyarrhythmias, cerebrovascular events, and systemic emboli based on stored device data: a subgroup analysis of TRENDS. *Heart Rhythm*. 2011;8:1416–1423. doi: 10.1016/j.hrthm.2011.04.022
164. Turakhia MP, Ziegler PD, Schmitt SK, Chang Y, Fan J, Than CT, Keung EK, Singer DE. Atrial fibrillation burden and short-term risk of stroke: case-crossover analysis of continuously recorded heart rhythm from cardiac electronic implanted devices. *Circ Arrhythm Electrophysiol*. 2015;8:1040–1047. doi: 10.1161/CIRCEP.114.003057
165. Chyou JY, Hunter TD, Mollenkopf SA, Turakhia MP, Reynolds MR. Individual and combined risk factors for incident atrial fibrillation and incident stroke: an analysis of 3 million at-risk US patients. *J Am Heart Assoc*. 2015;4:e001723. doi: 10.1161/JAHA.114.001723
166. Blacker DJ. In-hospital stroke. *Lancet Neurol*. 2003;2:741–746. doi: 10.1016/s1474-4422(03)00586-6
167. Jaakkola J, Hartikainen P, Kiviniemi TO, Nuotio I, Palomäki A, Hartikainen JEK, Ylitalo A, Mustonen P, Airaksinen KEJ. Distribution of ischemic strokes in patients with atrial fibrillation: the FibStroke Study. *Neurol Clin Pract*. 2019;9:330–336. doi: 10.1212/CPJ.0000000000000683
168. Berge E, Abdelnoor M, Nakstad PH, Sandset PM. Low molecular-weight heparin versus aspirin in patients with acute ischaemic stroke and atrial fibrillation: a double-blind randomised study: HAEST Study Group: Heparin in Acute Embolic Stroke Trial. *Lancet*. 2000;355:1205–1210. doi: 10.1016/s0140-6736(00)02085-7
169. Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, Biller J, Brown M, Demerschalk BM, Hoh B, et al; on behalf of the American Heart Association Stroke Council. Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association [published correction appears in *Stroke*. 2019;50:e440–e441]. *Stroke*. 2019;50:e344–e418. doi: 10.1161/STR.0000000000000211
170. Kleindorfer DO, Towfighi A, Chaturvedi S, Cockroft KM, Gutierrez J, Lombardi-Hill D, Kamel H, Kernan WN, Kittner SJ, Leira EC, et al. 2021 Guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association/American Stroke Association [published correction appears in *Stroke*. 2021;52:e483–e484]. *Stroke*. 2021;52:e364–e467. doi: 10.1161/STR.0000000000000375
171. Bessissow A, Khan J, Devereaux PJ, Alvarez-Garcia J, Alonso-Coello P. Postoperative atrial fibrillation in non-cardiac and cardiac surgery: an overview. *J Thromb Haemost*. 2015;13(suppl 1):S304–S312. doi: 10.1111/jth.12974
172. Goldman L. Supraventricular tachyarrhythmias in hospitalized adults after surgery: clinical correlates in patients over 40 years of age after major non-cardiac surgery. *Chest*. 1978;73:450–454. doi: 10.1378/chest.73.4.450
173. Danelich IM, Lose JM, Wright SS, Asirvatham SJ, Ballinger BA, Larson DW, Lovely JK. Practical management of postoperative atrial fibrillation after noncardiac surgery. *J Am Coll Surg*. 2014;219:831–841. doi: 10.1016/j.jamcollsurg.2014.02.038
174. Frendl G, Sodickson AC, Chung MK, Waldo AL, Gersh BJ, Tisdale JE, Calkins H, Aranki S, Kaneko T, Cassivi S, et al; American Association for Thoracic Surgeons. 2014 AATS guidelines for the prevention and management of perioperative atrial fibrillation and flutter for thoracic surgical procedures. *J Thorac Cardiovasc Surg*. 2014;148:e153–e193. doi: 10.1016/j.jtcvs.2014.06.036
175. Norhayati MN, Shaiful Bahari I, Zaharah S, Nik Hazlina NH, Mohammad Aimanazrul Z, Irfan M. Metoprolol for prophylaxis of postoperative atrial fibrillation in cardiac surgery patients: systematic review and meta-analysis. *BMJ Open*. 2020;10:e038364. doi: 10.1136/bmjopen-2020-038364
176. Filardo G, da Graca B, Sass DM, Hamilton J, Pollock BD, Edgerton JR. Preoperative beta-blockers as a coronary surgery quality metric: the lack of evidence of efficacy. *Ann Thorac Surg*. 2020;109:1150–1158. doi: 10.1016/j.athoracsur.2019.07.056
177. Auer J, Weber T, Berent R, Puschmann R, Hartl P, Ng CK, Schwarz C, Lehner E, Strasser U, Lassnig E, et al. A comparison between oral antiarrhythmic drugs in the prevention of atrial fibrillation after cardiac surgery: the pilot Study of Prevention of Postoperative Atrial Fibrillation (SPPAF), a randomized, placebo-controlled trial. *Am Heart J*. 2004;147:636–643. doi: 10.1016/j.ahj.2003.10.041
178. Brinkman W, Herbert MA, O'Brien S, Filardo G, Prince S, Dewey T, Magee M, Ryan W, Mack M. Preoperative beta-blocker use in coronary artery bypass grafting surgery: national database analysis. *JAMA Intern Med*. 2014;174:1320–1327. doi: 10.1001/jamainternmed.2014.2356
179. Daoud EG, Strickberger SA, Man KC, Goyal R, Deeb GM, Bolling SF, Pagani FD, Bitar C, Meissner MD, Morady F. Preoperative amiodarone as prophylaxis against atrial fibrillation after heart surgery. *N Engl J Med*. 1997;337:1785–1791. doi: 10.1056/nejm199712183372501
180. Chatterjee S, Sardar P, Mukherjee D, Lichstein E, Aikat S. Timing and route of amiodarone for prevention of postoperative atrial fibrillation after cardiac surgery: a network regression meta-analysis. *Pacing Clin Electrophysiol*. 2013;36:1017–1023. doi: 10.1111/pace.12140
181. Imazio M, Brucato A, Ferrazzi P, Rovere ME, Gandino A, Cemin R, Ferrua S, Belli R, Maestroni S, Simon C, et al. Colchicine reduces postoperative atrial fibrillation: results of the Colchicine for the Prevention of the Postpericardiotomy Syndrome (COPPS) atrial fibrillation substudy. *Circulation*. 2011;124:2290–2295. doi: 10.1161/circulationaha.111.026153
182. Imazio M, Brucato A, Ferrazzi P, Pullara A, Adler Y, Barosi A, Caforio AL, Cemin R, Chirillo F, Comoglio C, et al. Colchicine for prevention of postpericardiotomy syndrome and postoperative atrial fibrillation: the COPPS-2 randomized clinical trial. *JAMA*. 2014;312:1016–1023. doi: 10.1001/jama.2014.11026
183. Tabbalat RA, Hamad NM, Alhaddad IA, Hammoudeh A, Akasheh BF, Khader Y. Effect of Colchicine on the Incidence of Atrial Fibrillation in Open Heart Surgery Patients: END-AF trial. *Am Heart J*. 2016;178:102–107. doi: 10.1016/j.ahj.2016.05.006
184. Gaudino M, Sanna T, Ballman KV, Robinson NB, Hameed I, Audisio K, Rahouma M, Di Franco A, Soletti GJ, Lau C, et al. Posterior left pericardiotomy for the prevention of atrial fibrillation after cardiac surgery: an adaptive, single-centre, single-blind, randomised, controlled trial. *Lancet*. 2021;398:2075–2083. doi: 10.1016/S0140-6736(21)02490-9
185. Piccini JP, Ahlsson A, Dorian P, Gillinov MA, Kowey PR, Mack MJ, Milano CA, Perrault LP, Steinberg JS, Waldron NH, et al. Design and rationale of a phase 2 study of NeurOtoxin (botulinum toxin type a) for the prevention of post-operative atrial fibrillation: the NOVA study. *Am Heart J*. 2022;245:51–59. doi: 10.1016/j.ahj.2021.10.114
186. Phan K, Xie A, Tsai YC, Kumar N, La Meir M, Yan TD. Bialtrial ablation vs. left atrial concomitant surgical ablation for treatment of atrial fibrillation: a meta-analysis. *Europace*. 2015;17:38–47. doi: 10.1093/europace/euu220
187. Badhwar V, Rankin JS, Damiano RJ Jr, Gillinov AM, Bakaeen FG, Edgerton JR, Philpott JM, McCarthy PM, Bolling SF, Roberts HG, et al. The Society of Thoracic Surgeons 2017 clinical practice guidelines for the surgical treatment of atrial fibrillation. *Ann Thorac Surg*. 2017;103:329–341. doi: 10.1016/j.athoracsur.2016.10.076
188. Suzuki K, Miyamoto K, Ueda N, Nakajima K, Kamakura T, Wada M, Yamagata K, Ishibashi K, Inoue Y, Noda T, et al. Relationship between electrical gaps after maze procedure and atrial tachyarrhythmias and ablation outcomes after cardiac surgery and concomitant maze procedure. *Heart Vessels*. 2021;36:675–685. doi: 10.1007/s00380-020-01737-3
189. Whitlock RP, Belley-Cote EP, Paparella D, Healey JS, Brady K, Sharma M, Reents W, Budera P, Baddour AJ, Fila P, et al. Left atrial appendage occlusion during cardiac surgery to prevent stroke. *N Engl J Med*. 2021;384:2081–2091. doi: 10.1056/NEJMoa2101897
190. Ellis CR, Aznaurov SG, Patel NJ, Williams JR, Sandler KL, Hoff SJ, Ball SK, Whalen SP, Carr JJ. Angiographic efficacy of the Atriclip left atrial appendage exclusion device placed by minimally invasive thoracoscopic approach. *JACC Clin Electrophysiol*. 2017;3:1356–1365. doi: 10.1016/j.jacep.2017.03.008
191. Aryana A, Singh SK, Singh SM, O'Neill PG, Bowers MR, Allen SL, Lewandowski SL, Vierra EC, d'Avila A. Association between incomplete surgical ligation of left atrial appendage and stroke and systemic embolization. *Heart Rhythm*. 2015;12:1431–1437. doi: 10.1016/j.hrthm.2015.03.028
192. Kanderian AS, Gillinov AM, Pettersson GB, Blackstone E, Klein AL. Success of surgical left atrial appendage closure: assessment by transesophageal echocardiography. *J Am Coll Cardiol*. 2008;52:924–929. doi: 10.1016/j.jacc.2008.03.067
193. Crijns HJ, Van Gelder IC, Kingma JH, Dunselman PH, Gosselink AT, Lie KI. Atrial flutter can be terminated by a class III antiarrhythmic drug but not by a class IC drug. *Eur Heart J*. 1994;15:1403–1408. doi: 10.1093/oxfordjournals.eurheartj.a060402

194. Tai CT, Chen SA, Feng AN, Yu WC, Chen YJ, Chang MS. Electropharmacologic effects of class I and class III antiarrhythmic drugs on typical atrial flutter: insights into the mechanism of termination. *Circulation*. 1998;97:1935–1945. doi: 10.1161/01.cir.97.19.1935
195. Stambler BS, Wood MA, Ellenbogen KA. Antiarrhythmic actions of intravenous ibutilide compared with procainamide during human atrial flutter and fibrillation: electrophysiological determinants of enhanced conversion efficacy. *Circulation*. 1997;96:4298–4306. doi: 10.1161/01.cir.96.12.4298
196. Kafkas NV, Patsilinos SP, Mertzanos GA, Papageorgiou KI, Chaveles JI, Dagadaki OK, Kelesidis KM. Conversion efficacy of intravenous ibutilide compared with intravenous amiodarone in patients with recent-onset atrial fibrillation and atrial flutter. *Int J Cardiol*. 2007;118:321–325. doi: 10.1016/j.ijcard.2006.07.017
197. Bianconi L, Castro A, Dinelli M, Alboni P, Pappalardo A, Richiardi E, Santini M. Comparison of intravenously administered dofetilide versus amiodarone in the acute termination of atrial fibrillation and flutter: a multicentre, randomized, double-blind, placebo-controlled study. *Eur Heart J*. 2000;21:1265–1273. doi: 10.1053/euhj.1999.2039
198. Falk RH. Proarrhythmia in patients treated for atrial fibrillation or flutter. *Ann Intern Med*. 1992;117:141–150. doi: 10.7326/0003-4819-117-2-141
199. Crozier IG, Ikram H, Kenealy M, Levy L. Flecainide acetate for conversion of acute supraventricular tachycardia to sinus rhythm. *Am J Cardiol*. 1987;59:607–609. doi: 10.1016/0002-9149(87)91178-7
200. Giehm-Reese M, Kronborg MB, Lukac P, Kristiansen SB, Nielsen JM, Johannessen A, Jacobsen PK, Djurhuus MS, Riahi S, Hansen PS, et al. Recurrent atrial flutter ablation and incidence of atrial fibrillation ablation after first-time ablation for typical atrial flutter: a nation-wide Danish cohort study. *Int J Cardiol*. 2020;298:44–51. doi: 10.1016/j.ijcard.2019.07.077
201. Spector P, Reynolds MR, Calkins H, Sondhi M, Xu Y, Martin A, Williams CJ, Sledge I. Meta-analysis of ablation of atrial flutter and supraventricular tachycardia. *Am J Cardiol*. 2009;104:671–677. doi: 10.1016/j.amjcard.2009.04.040
202. Pérez FJ, Schubert CM, Parvez B, Pathak V, Ellenbogen KA, Wood MA. Long-term outcomes after catheter ablation of cavo-tricuspid isthmus dependent atrial flutter: a meta-analysis. *Circ Arrhythm Electrophysiol*. 2009;2:393–401. doi: 10.1161/CIRCEP.109.871665
203. Maskoun W, Pino MI, Ayoub K, Llanos OL, Almomani A, Nairooz R, Hakeem A, Miller J. Incidence of atrial fibrillation after atrial flutter ablation. *JACC Clin Electrophysiol*. 2016;2:682–690. doi: 10.1016/j.jacep.2016.03.014
204. Perino AC, Fan J, Schmitt SK, Askari M, Kaiser DW, Deshmukh A, Heidenreich PA, Swan C, Narayan SM, Wang PJ, et al. Treating specialty and outcomes in newly diagnosed atrial fibrillation: from the TREAT-AF study. *J Am Coll Cardiol*. 2017;70:78–86. doi: 10.1016/j.jacc.2017.04.054
205. Varma N, Marrouche NF, Aguinaga L, Albert CM, Arbelo E, Choi JI, Chung MK, Conte G, Dagher L, Epstein LM, et al. HRS/EHRA/APHRS/IAHRS/ACC/AHA worldwide practice update for telehealth and arrhythmia monitoring during and after a pandemic. *Circ Arrhythm Electrophysiol*. 2020;13:e009007. doi: 10.1161/CIRCEP.120.009007
206. Varma N, Cygankiewicz I, Turakhia MP, Heidbuchel H, Hu YF, Chen LY, Couderc JP, Cronin EM, Estep JD, Grieten L, et al. 2021 ISHNE/HRS/EHRA/APHRS expert collaborative statement on mHealth in arrhythmia management: digital medical tools for heart rhythm professionals: from the International Society for Holter and Noninvasive Electrocardiology/Heart Rhythm Society/European Heart Rhythm Association/Asia-Pacific Heart Rhythm Society. *Circ Arrhythm Electrophysiol*. 2021;14:e009204. doi: 10.1161/CIRCEP.120.009204
- 207a. Sanna T, Diener HC, Passman RS, Di Lazzaro V, Bernstein RA, Morillo CA, Rymer MM, Thijs V, Rogers T, Beckers F, et al; CRYSTAL AF Investigators. Cryptogenic stroke and underlying atrial fibrillation. *N Engl J Med*. 2014;370:2478–2486. doi: 10.1056/NEJMoa1313600
207. Perez MV, Mahaffey KW, Hedlin H, Rumsfeld JS, Garcia A, Ferris T, Balasubramanian V, Russo AM, Rajmane A, Cheung L, et al. Large-scale assessment of a smartwatch to identify atrial fibrillation. *N Engl J Med*. 2019;381:1909–1917. doi: 10.1056/nejmoa1901183
208. Ha ACT, Verma S, Mazer CD, Quan A, Yanagawa B, Latter DA, Yau TM, Jacques F, Brown CD, Singal RK, et al; SEARCH AF Cardiolink-1 Investigators. Effect of continuous electrocardiogram monitoring on detection of undiagnosed atrial fibrillation after hospitalization for cardiac surgery: a randomized clinical trial. *JAMA Netw Open*. 2021;4:e2121867. doi: 10.1001/jamanetworkopen.2021.21867
209. Gundlund A, Kümler T, Bonde AN, Butt JH, Gislason GH, Torp-Pedersen C, Køber L, Olesen JB, Fosbøl EL. Comparative thromboembolic risk in atrial fibrillation with and without a secondary precipitant: Danish nationwide cohort study. *BMJ Open*. 2019;9:e028468. doi: 10.1136/bmjopen-2018-028468
210. Kirchhof P, Camm AJ, Goette A, Brandes A, Eckardt L, Elvan A, Fetsch T, van Gelder IC, Haase D, Haegeli LM, et al. Early rhythm-control therapy in patients with atrial fibrillation. *N Engl J Med*. 2020;383:1305–1316. doi: 10.1056/NEJMoa2019422
211. Packer DL, Mark DB, Robb RA, Monahan KH, Bahnson TD, Poole JE, Noseworthy PA, Rosenberg YD, Jeffries N, Mitchell LB, et al. Effect of catheter ablation vs antiarrhythmic drug therapy on mortality, stroke, bleeding, and cardiac arrest among patients with atrial fibrillation: the CABANA randomized clinical trial. *JAMA*. 2019;321:1261–1274. doi: 10.1001/jama.2019.0693
212. Wazni OM, Dandamudi G, Sood N, Hoyt R, Tyler J, Durrani S, Niebauer M, Makati K, Halperin B, Gauri A, et al. Cryoballoon ablation as initial therapy for atrial fibrillation. *N Engl J Med*. 2021;384:316–324. doi: 10.1056/nejmoa2029554
213. Marrouche NF, Brachmann J, Andresen D, Siebels J, Boersma L, Jordaens L, Merkely B, Pokushalov E, Sanders P, Proff J, et al. Catheter ablation for atrial fibrillation with heart failure. *N Engl J Med*. 2018;378:417–427. doi: 10.1056/nejmoa1707855
214. Packer DL, Piccini JP, Monahan KH, Al-Khalidi HR, Silverstein AP, Noseworthy PA, Poole JE, Bahnson TD, Lee KL, Mark DB. Ablation versus drug therapy for atrial fibrillation in heart failure: results from the CABANA trial. *Circulation*. 2021;143:1377–1390. doi: 10.1161/circulationaha.120.050991
215. Wang TJ, Parise H, Levy D, D'Agostino RB Sr, Wolf PA, Vasan RS, Benjamin EJ. Obesity and the risk of new-onset atrial fibrillation. *JAMA*. 2004;292:2471–2477. doi: 10.1001/jama.292.20.2471
216. Wanhaita N, Messerli FH, Bangalore S, Gami AS, Somers VK, Steinberg JS. Atrial fibrillation and obesity: results of a meta-analysis. *Am Heart J*. 2008;155:310–315. doi: 10.1016/j.ahj.2007.10.004
217. Overvad TF, Rasmussen LH, Skjøth F, Overvad K, Lip GY, Larsen TB. Body mass index and adverse events in patients with incident atrial fibrillation. *Am J Med*. 2013;126:640.e9–640.e17. doi: 10.1016/j.amjmed.2012.11.024
218. Gami AS, Pressman G, Caples SM, Kanagala R, Gard JJ, Davison DE, Malouf JF, Ammash NM, Friedman PA, Somers VK. Association of atrial fibrillation and obstructive sleep apnea. *Circulation*. 2004;110:364–367. doi: 10.1161/01.cir.0000136587.68725.8e
219. Linz D, McEvoy RD, Cowie MR, Somers VK, Nattel S, Lévy P, Kalman JM, Sanders P. Associations of obstructive sleep apnea with atrial fibrillation and continuous positive airway pressure treatment: a review. *JAMA Cardiol*. 2018;3:532–540. doi: 10.1001/jamacardio.2018.0095
220. Lip GY, Coca A. Hypertension and cardiac arrhythmias. *Eur Heart J*. 2017;38:223–225. doi: 10.1093/eurheartj/ehw664
221. Huxley RR, Filion KB, Konety S, Alonso A. Meta-analysis of cohort and case-control studies of type 2 diabetes mellitus and risk of atrial fibrillation. *Am J Cardiol*. 2011;108:56–62. doi: 10.1016/j.amjcard.2011.03.004
222. Mozaffarian D, Furberg CD, Psaty BM, Siscovick D. Physical activity and incidence of atrial fibrillation in older adults: the Cardiovascular Health Study. *Circulation*. 2008;118:800–807. doi: 10.1161/circulationaha.108.785626
223. Garnvik LE, Malmö V, Janszky I, Wisløff U, Loennechen JP, Nes BM. Physical activity modifies the risk of atrial fibrillation in obese individuals: the HUNT3 study. *Eur J Prev Cardiol*. 2018;25:1646–1652. doi: 10.1177/2047487318784365
224. Cha MJ, Oh GC, Lee H, Park HE, Choi SY, Oh S. Alcohol consumption and risk of atrial fibrillation in asymptomatic healthy adults. *Heart Rhythm*. 2020;17:2086–2092. doi: 10.1016/j.hrthm.2020.07.010
225. Larsson SC, Drca N, Wolk A. Alcohol consumption and risk of atrial fibrillation: a prospective study and dose-response meta-analysis. *J Am Coll Cardiol*. 2014;64:281–289. doi: 10.1016/j.jacc.2014.03.048
226. Lim C, Kim TH, Yu HT, Lee SR, Cha MJ, Lee JM, Park J, Park JK, Kang KW, Shim J, et al. Effect of alcohol consumption on the risk of adverse events in atrial fibrillation: from the COMPARISON study of Drugs for symptom control and complication prevention of Atrial Fibrillation (CODE-AF) registry. *Europace*. 2021;23:548–556. doi: 10.1093/europace/eaab340
227. Pathak RK, Middeldorp ME, Meredith M, Mehta AB, Mahajan R, Wong CX, Twomey D, Elliott AD, Kalman JM, Abhayaratna WP, et al. Long-term effect of goal-directed weight management in an atrial fibrillation cohort: a long-term follow-up study (LEGACY). *J Am Coll Cardiol*. 2015;65:2159–2169. doi: 10.1016/j.jacc.2015.03.002
228. Pathak RK, Middeldorp ME, Lau DH, Mehta AB, Mahajan R, Twomey D, Alasady M, Hanley L, Antic NA, McEvoy RD, et al. Aggressive risk factor reduction study for atrial fibrillation and implications for the outcome of

ablation: the ARREST-AF cohort study. *J Am Coll Cardiol*. 2014;64:2222–2231. doi: 10.1016/j.jacc.2014.09.028

229. Abed HS, Wittert GA, Leong DP, Shirazi MG, Bahrami B, Middeldorp ME, Lorimer MF, Lau DH, Antic NA, Brooks AG, et al. Effect of weight reduction and cardiometabolic risk factor management on symptom burden and severity in patients with atrial fibrillation: a randomized clinical trial. *JAMA*. 2013;310:2050–2060. doi: 10.1001/jama.2013.280521
230. Malmö V, Nes BM, Amundsen BH, Tjønnå AE, Støylen A, Rossvoll O, Wisloff U, Loennechen JP. Aerobic interval training reduces the burden of atrial fibrillation in the short term: a randomized trial. *Circulation*. 2016;133:466–473. doi: 10.1161/circulationaha.115.018220
231. Osbak PS, Mourier M, Kjaer A, Henriksen JH, Kofoed KF, Jensen GB. A randomized study of the effects of exercise training on patients with atrial fibrillation. *Am Heart J*. 2011;162:1080–1087. doi: 10.1016/j.ahj.2011.09.013
232. Middeldorp ME, Pathak RK, Meredith M, Mehta AB, Elliott AD, Mahajan R, Twomey D, Gallagher C, Hendriks JML, Linz D, et al. PREVENTion and regReSSive Effect of weight-loss and risk factor modification on Atrial Fibrillation: the REVERSE-AF study. *Europace*. 2018;20:1929–1935. doi: 10.1093/europace/euy117
233. Chung MK, Eckhardt LL, Chen LY, Ahmed HM, Gopinathannair R, Joglar JA, Noseworthy PA, Pack QR, Sanders P, Trulock KM; on behalf of the American Heart Association Electrocardiography and Arrhythmias Committee and Exercise, Cardiac Rehabilitation, and Secondary Prevention Committee of the Council on Clinical Cardiology; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular and Stroke Nursing; and Council on Lifestyle and Cardiometabolic Health. Lifestyle and risk factor modification for reduction of atrial fibrillation: a scientific statement from the American Heart Association. *Circulation*. 2020;141:e750–e772. doi: 10.1161/CIR.0000000000000748